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ABSTRACT 
 Although there is a major decline of heavy metal usage in most Western 
countries, the industrial use of the metals is not prohibited world-wide and their 
effects on human health are still obvious. Heavy metal resuspension, through the 
environmental dust and soil accumulation, make them a dangerous enemy for 
human health, as the exposure to them cannot be avoided. The genotoxic effects 
of most of the metals are mostly well-established; the most common ones have 
identified to be the generation of ROS and the inhibition of DNA repair pathways. 
However, a big variety of co-interacting mechanisms makes it particularly 
difficult to identify the specific action of heavy metals inside the body. The 
enzyme Topoisomerase-I acts on the DNA topological stability and previous 
works have shown inhibitory effects on the enzyme, can affect DNA 
sustainability. In this project, the toxicity of cadmium, lead, copper and zinc on 
human lung fibroblasts at physiological levels has been studied. Also, the 
inhibition of the enzyme Topoisomerase-I, is suggested as a potential mechanism 
and the purification of the protein was attempted for future work. The present 
study gives additional evidence of the genotoxic effects of the heavy metals and 
their inhibitory ability on Topoisomerase-I through cleavage and relaxation 
assays; and suggests further research in order for the leading pathways of heavy-
metal induced cancer to be comprehended. 
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ALAD Delta-aminolevulinic acid dehydratase 
APS Ammonium Persulfate 
ARDS Adult Respiratory Distress Symptom 
ATP Adenosine Triphosphate 
ATSDR 
Agency for Toxic Substances and Disease 
Registry 
BA Betulinic Acid 
BER Base Excision Repair 





DSB Double Strand Break 
EDTA Ethylenediaminetetraacetic acid 
GFP Green Fluorescence Protein 
GSH Glutathione Reductase 
GST Glutathione 
hCTR1 human Copper Transport Protein 1 
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IARC International Agency for research on Cancer 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IQ Intelligence Quotivent 
IUPAC 
International Union of Pure and Applied 
Chemistry 
L.C.50 Lethal Concentration 50 
MD Menkes Disease 
MMR Mismatch Repair 
MT Metallothionein 
NER Nucleotide Excision Repair 
OSHA 
Occupational Safety  and Health 
Administation 




PVC Polyvinyl Chloride 
ROS Reactive Oxygen Species 
SCE Sister Chromatid Exchange 
SLC Solute Linked Carrier 
SOD Superoxide Dismutase 
SSB Single Strand Break 
TAE Tris Acetate EDTA  
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TBE Tris Borate EDTA 
TBST Tris Buffered Saline with Tween 
Topo-I Topoisomerase-I 
Topo-I-cc Topoisomerase-I- cleavage complexes 
WD Wilson's Disease 
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1.1. Introduction to heavy metals 
 The term "heavy metal" is often used to describe a specific group of 
metals; however, it has been associated with various metal properties 
throughout the years. The very first and most common use of the term "heavy 
metal" was to describe metals with high environmental contamination risk and 
potential toxicity. In addition, it has been used to describe metals based on their 
density (Jarup, 2003). Later on, authors started to associate this term with the 
mass or even the atomic weight of the metals. Although it was a much more 
accurate way to describe the metals and closer to the periodic table, there is no 
description of it in the International Union of Pure and Applied Chemistry 
(IUPAC) Compendium of Chemical Terminology (Duffus, 2002). Due to the 
imprecision of the term, it should be noted that in this work the term is used to 
describe metals which combine toxicity and high specific density. 
 In this thesis, metals such as cadmium, lead, zinc and copper have been 
utilised and their toxic effects are investigated. These heavy metals have atomic 
masses greater than non-trace metals like potassium, calcium, and magnesium. 
Their ions are noted for their toxicity and they are also chemical elements with a 
specific gravity at least five times greater than the specific gravity of water, which 
is the defining value that is currently most. 
 Heavy metals are found naturally in the Earth's crust and are released to 
the environment via natural phenomena, such as rock erosion and volcanic 
explosion. However, the industrial development added anthropogenic factors to 
metal emissions, such as mining and excavation of metals. Furthermore, the 
excessive industrial exploitation of metals has contributed to water and soil 
pollution due to industrial waste; consequently, the exposure, of livestock and 
finally humans, to metals became inevitable. The heedless usage of metals, 
without assessing their toxicity first, led to numerous diseases. A clear example is 
that of leaded gasoline, which was used for years, polluting the environment 
irreversibly, causing exposed individuals to suffer from bone diseases and 
neurological impairment. The most important fact about heavy metal pollution is 
that metals do not degrade over the years- as organic waste does- whereas they 
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resuspend via the air dust and accumulate within the soil (Beyersmann and 
Hartwig, 2008).  
 The health impact of long-term heavy metal exposure is well known. The 
cancerogenic effects of heavy metals have been demonstrated in an extensive 
bibliography, including meta-analysis and animal studies, with the findings being 
certified by the International Agency for Research on Cancer (IARC) and World 
Health Organisation (WHO) committees’ agreements.  Among metals, cadmium, 
beryllium, arsenic, chromium and nickel have been classified as human 
carcinogens and several others were classified as possible carcinogens (IARC, 
1993; WHO/IFCS/FSC/WG, 2008). Metal toxicity can arise from the oxidation 
state, the charge and the ionic radii of the metal ions. Regarding metal 
compounds, key factors are their coordination number and geometry. These 
properties, when found to be comparable to those of other essential elements, 
could replace such elements and lead to the malfunctioning of the related 
enzymes and proteins, as it happens at cadmium which can replace calcium 
affecting the bone structure (reviewed in Beyersmann and Hartwig, 2008). 
 Although most heavy metals are toxic, there are others that are essential 
trace elements, such as copper, zinc, nickel and calcium. However, when their 
levels exceed a certain range, toxic or deficiency effects could appear as well.  
Overdose or deficiency could occur either by a high exposure or malnutrition 
respectively, or by mutation in genes of their carrier’s enzymes. For example, 
mutations in genes related to copper transport enzymes can cause the very well-
known Menkes and Wilson diseases, causing copper toxicity or deficiency 
respectively. However, the low physiological levels of those metals, in 
combination with the lack of early biomarkers of exposure set the early diagnosis 
as a difficult task. 
  
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 8 - 
 
1.2. Metal genotoxicity/ carcinogenicity 
 Metal toxicity and carcinogenicity depend on very complex mechanisms, 
which are still not entirely clear for most metals. The toxicity of a metal depends 
on the metal compound bioavailability, i.e. the mechanisms regulating the metal 
absorbance at the cell membrane, the intracellular distribution and the binding 
to cellular macromolecules. On the other hand, carcinogenicity can depend on the 
combination of the production of Reactive Oxygen Species (ROS), DNA repair 
modulation and disturbances of signal transduction pathways (reviewed in 
Beyersmann and Hartwig, 2008). The involved mechanisms are so inter-
connected and complex that it is difficult to single out one mechanism. For 
example, there are metals like cadmium, which are not directly redox active, but 
act indirectly, by inhibiting antioxidant enzymes, such as the superoxide 
dismutase, catalase and glutathione peroxidase. All these pathways will be 




 The environmental emission of cadmium on the Earth’s crust is mainly 
due to sedimentary rocks and in water it occurs due to the weathering and 
erosion of rocks, which end up in rivers and the sea. Other major natural sources 
of cadmium are volcanic activity and forest fires (WHO/IPCS, 1992; Cook, 1995; 
Nriagu, 1989). Anthropogenic sources of cadmium emission include nickel-
cadmium batteries, pigments, ceramics, paints, stabilized Polyvinyl Chloride 
(PVC) products and electronic components (Bertin and Averbeck, 2006). Sources 
of cadmium emission also include, non-ferrous metal production, stationary 
fossil fuel combustion and waste incineration, steel and cement production and 
phosphate fertilizers (WHO, 2007).  
 Cadmium is known for its toxicity and its health effects on humans, which 
can lead to organ damage and cancer. Cadmium accumulation in the kidneys 
makes it nephrotoxic, while several bone damages have been recorded as well 
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(reviewed in IARC, 1993). Cadmium can also be blamed for having significant 
cellular effects, as it affects cell proliferation, the cell cycle, cell signaling, DNA 
replication and repair, differentiation and apoptosis. ROS are also implicated in 
cadmium toxicity (Bertin and Averbeck, 2006). 
 It has been shown that the human body absorbs cadmium via inhalation, 
ingestion and dermal exposure. The major source of cadmium exposure which 
consists the 90% of the total intake among the non-smoking population in non-
polluted areas is through diet (WHO/IPCS, 1992; WHO, 2007). It is estimated that 
approximately 80% of the ingested cadmium comes from cereals and vegetables, 
while in drinking water usually is between 0.01 and 1μg/l of the total ingestion 
(WHO, 2007). However, the very low cadmium concentration in drinking water 
makes it an insignificant contribution to total body cadmium levels (Olsson et al., 
2002). 
 Although inhaled cadmium makes up a smaller part of the total cadmium 
body burden than the ingested one, pulmonary cadmium absorption is higher, 
ranging from 10% to 50% (WHO/IPCS, 1992), while gastrointestinal absorption 
accounts for only a small percentage (Järup et al., 1998). As tobacco contains 
cadmium at high levels, it is important to highlight that smokers have about 4-5 
times higher cadmium blood levels (nearly 1.5μg/l) and two times higher kidney 
cortex cadmium concentration (20-30μg/g per weight) than non-smokers (WHO, 
2007). 
 
 1.3.1. Cadmium kinetics in human body 
 Following absorption, cadmium accumulates primarily in the kidneys and 
has a biological half-life ranging between 10 to 35 years. Long-term cadmium 
exposure could be revealed by urinary cadmium concentrations as the kidney 
releases it gradually, whereas recent exposure could be revealed by blood 
cadmium levels (WHO/IFCS/FSC/WG, 2008). 
 The metabolism and mobilisation of cadmium in humans and animals 
mainly depends on enzyme's metallothionein ability to bind to metals, as its 
name declares. Metallothioneins (MT) are a family of cysteine-rich proteins 
which have the capacity to bind to heavy metals through the thiol group of their 
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 10 - 
 
cysteine residues. In the human body, MT are mainly synthesised in the liver and 
the kidneys, and tend to accumulate there. MT production is induced by cadmium 
presence in the body, creating a defense mechanism against cadmium toxicity in 
tissues and organs, because it has the ability to bind with metals (reviewed in 
Astrid et al., 2009). 
 After cadmium exposure, either at the gastrointestinal or the respiratory 
system, a part of it is absorbed by the body and binds to MT forming a cadmium-
Metallothionein (Cd-MT) complex, which can travel within the bloodstream. 
When this complex reaches the kidneys, it is filtered at the glomerulus and may 
be re-absorbed from the filtrate in the proximal tubules (Foulkes, 1982). Inside 
the tubules, the Cd-MT complex is degraded and cadmium is released. As a result, 
the free cadmium accumulates in kidney tubules and damages the tubular cells 
(Dorian et al., 1992). 
 
 1.3.2. Health problems following cadmium 
exposure 
 Several health effects have been monitored after cadmium exposure. The 
kidney is the main organ where cadmium accumulates causing renal malfunction 
(WHO/IPCS, 1992). Cadmium effects on calcium metabolism makes bones a 
tissue sensitive to cadmium exposure, as several bone diseases have been noted 
after exposure to it. It should also be noted, that cadmium is carcinogenic for 
several organs, with lungs being the most well established ones (Figure 1) 
(WHO/IPCS, 1992). In 1993, the IARC classified cadmium as a human carcinogen 
(Group 1) (IARC, 1993), after strong evidence was found in animal models and 
human epidemiological studies. For example, lung adenocarcinomas were 
developed in rats after cadmium inhalation (Glaser et al., 1990; Takenaka et al., 
1983).  
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Figure 1: Sites affected by cadmium exposure. 
This image illustrates the most common locations in the human body, in which health 
effects including cancer development have been associated with cadmium exposure. 
Lungs are the most well-established place based on studies of animal cadmium 
inhalation and on epidemiological human studies (Waalkes, 2003). Studies on breast and 
reproductive system cancers show a geographic correlation. The majority of studies in 
Western countries confirm the carcinogenicity of cadmium at these sites, however 
studies on Asian population, found no significant correlation (Aggett, 1999). There has 
not been a well-established relation to pancreas and kidneys cancer, however studies on 
this matter have limitations (WHO, 2007). Even if the relation of cadmium exposure to 
kidney cancer is not very clear, the development of renal damage that occurs after 
cadmium ingestion is well known, with excessive proteinuria being the major symptom. 
Bone damages are one of the most severe consequences of cadmium exposure, causing 
severe painful diseases, such as osteoporosis, easily fractured bones and Itai-Itai disease 
(WHO, 2007) (adapted from Häggström, 2014). 
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 1.3.2.1. Kidney and Bone damages 
 Renal tubular damage occurs in humans after a prolonged intake of 
cadmium, which is estimated at 140-260μg of cadmium per day or a short 
cumulative intake of about 2000mg. An initial symptom, that exposed workers 
show, is increased urinary excretion of proteins, such as the β2-microglobulin 
transferrin, which indicates renal lesion (Järup, 1998). Although it does not show 
any subjective symptoms or disease, tubular proteinuria can be reversible even 
after past exposure to high levels of cadmium. Workers, occupationally exposed 
to cadmium, have shown a high prevalence of kidney stones (reviewed in WHO, 
2007; Trzcinka-Ochocka et al., 2002). 
 Cadmium exposure affects calcium and phosphorous metabolism, as well 
as vitamin D-blood level, resulting in painful bone diseases, such as osteoporosis, 
osteomalacia and spontaneous bone fracture. It has been shown that women are 
affected the most supposedly due to their natural calcium deficiency (WHO/IPCS, 
1992). Cadmium exposure has been associated with low bone density in 
occupational and environmental settings leading to increasing risk for 
osteoporosis and bone fractures (Alfven et al., 2000; Staessen et al., 1999). 
 Two mechanisms have been suggested regarding cadmium’s role in bone 
damage. The first includes indirect bone lesions caused by the ability of cadmium 
to accumulate in tubular cells causing decreased cellular functions. As a result, 
the cells cannot metabolize the vitamin D3, which in turn decreases calcium 
absorption, and bones are eventually damaged (WHO/IPCS, 1992). In addition, 
cadmium substitute calcium in calcium-depended proteins, changing the normal 
protein function, in this way affecting calcium metabolism, thus bones get 
damaged (Beyersmann and Hartwig, 2008). The second suggested mechanism is 
direct effect that cadmium has at bones, as skeletal injuries were present at 
exposure to cadmium levels which have not be found to be  related to kidney 
damage (Honda et al., 2003; Wang and Bhattacharyya, 1993). Experiments on 
mice showed that cadmium stimulates bone demineralization by enhancing bone 
resorption and reduced bone formation (Regunathan et al., 2003; Dohi et al., 
1993). 
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 13 - 
 
 The most severe clinical syndrome noted, which is commonly referred to 
as Itai-Itai disease, occurs from cadmium poisoning after prolonged ingestion 
and has been observed in Japanese mine workers and farmers (Inaba et al., 
2005). The clinical symptoms of this disease include renal and bone injury, with 
bone damage and pain being the main characteristics. Initially, it starts with 
painful sites, which gradually spread all over the body with coexisting 
osteomalacia and osteoporosis. Bone fractures could be easily caused by the 
slightest pressure, such as coughing, and skeletal deformities can develop. The 
most recent data suggests that women are more susceptible to bone injuries, as a 
meta-analysis study showed that until 2004, out of 188 recognized patients, 185 
of them were female (reviewed in Inaba et al., 2005). 
 
 1.3.3. Genotoxic effects of cadmium 
 Studies in vivo and in vitro have shown that cadmium induces oxidative 
stress, inhibition of DNA repair systems and that it also affects cell proliferation 
and tumour suppressor functions (reviewed in detail by Bertin and Averbeck, 
2006; Valko et al., 2006; Beyersmann and Hartwig, 2008; Waisberg et al., 2003) 
(figure 2). However, the effects on DNA synthesis and cell proliferation differ in 
relation to cadmium dose and compound used. Briefly, at very low cadmium 
concentrations the rate of DNA synthesis and cell division increase, whereas at 
higher cadmium concentrations DNA synthesis and cell division are inhibited 
(Misra et al., 2003; Vonzglinicki et al., 1992). In addition, it has been shown that 
cadmium salts enhance do not directly cause DNA damage in cell extracts or with 
isolated DNA. For example, non-toxic metal concentrations have been treated at 
different organs of CD-I male mice after inhalation. Although there was no 
induced direct DNA damage, induction of lipid peroxidation and increased free 
radicals levels have been detected, suggesting indirect cause of DNA damages 
(Valverde et al., 2001). 
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Figure 2: Molecular effects involved in cadmium carcinogenesis 
Cadmium has been found to inhibit the DNA repair system, decrease antioxidants 
enzymes, induce the proto-oncogenes and inhibit the DNA methylation; all of them could 
potentially lead to malignant tumour development. Also, its ability to damage the cells 
could cause the cell to commit suicide, the known apoptosis (reviewed in and adapted 
from Waisberg et al., 2003). 
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 More evidence has been given on cadmium's indirect genotoxicity and not 
redox activity, with the most possible mechanism that has been proposed being 
the indirect production of ROS (Waalkes and Poirier, 1984; O'Brien and 
Salacinski, 1998; Galan et al., 2001). This indirect production of ROS derives from 
cadmium’s ability to decrease the cellular defence against oxidative stress by 
inhibiting antioxidant enzymes. Animal studies, mainly on rats, have shown 
decreased levels of catalase, superoxide dismutase (SOD), glutathione reductase 
(GSH) and glutathione peroxidase after cadmium exposure (Casalino et al., 2002; 
Waisberg et al., 2003; Sarkar et al., 1998; Tatrai et al., 2001). MT and GSH play a 
detoxification role by binding to cadmium and not allowing it to interact with 
other cellular targets, e.g. blocking the generation of ROS induced by cadmium 
(IARC, 1993; Eneman et al., 2000). However, at elevated cadmium levels, the cells 
reach the limits of MT and GSH levels and, as a result cadmium toxicity occurs 
(Liu et al., 1990).  
 The effects of cadmium's on DNA repair mechanisms have been 
demonstrated for several different DNA repair enzymes in low non-cytotoxic 
concentrations. Many studies have shown the ability of cadmium to inhibit or 
diminish the activity of several repair proteins. The DNA repair systems that are 
chiefly affected by cadmium are mismatch repair (MMR), nucleotide excision 
repair (NER) and base excision repair (BER) where different proteins are 
affected by cadmium (reviewed in Bertin and Averbeck, 2006). A few examples of 
the enzymes affected by cadmium are given in Table 1.   
 Misra et al. (2003) have reported that after cadmium exposure some 
proto-oncogenes genes are over expressed and some proteins are up regulated. 
Some of the most extensively studied genes and proteins which play an 
important role in cell proliferation and differentiation are the proto-oncogenes c-
fos, c-jun and c-myc genes and GRB2 and SHC proteins. From the early 90s, these 
over-expressions have been noticed in mammalian cells such as rat myoblasts 
and kidney cells, pig kidney cells, rat and human mesangial cells and human 
prostate epithelial cells (Abshire et al., 1996; Tang and Enger, 1993; Matsuoka 
and Call, 1995; Templeton et al., 1998; Wang and Templeton, 1998). These are 
mitogenic growth signals that promote cell proliferation and also the expression 
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of translation factors, therefore they amplify the proliferation of mutated genes, 
eventually leading to carcinogenicity (Joseph et al., 2004; Pei and Ringertz, 1990; 
Waisberg et al., 2003; Ren et al., 2003; Parsell, 1994; Singhal et al., 1987). 
 The genes affected by cadmium are not limited to proto-oncogenes and 
stress response ones. Various other genes are involved which take part in cell 
defense mechanisms, cell death, aging, transport, energy metabolism and ionic 
homeostasis, as well as the suppression of genes involved in protein synthesis 
(reviewed in Waisberg et al., 2003; Bertin and Averbeck, 2006). Particularly, 
regarding programmed cell death, it was found that cadmium for example 
activates caspase-9 in HL60 leukemia cells (Kondoh et al., 2002). It has also been 
seen that it disrupts the structure of p53, not allowing it to bind to DNA (Meplan 
et al., 1999). In conclusion, it could be said that cadmium interferes with cellular 
mechanisms through several pathways; however the exact contribution of those 
mechanisms to the carcinogenicity and toxicity is not possible to be estimated 
yet. 
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 ATP hydrolysys 





NER XPA mammalian 




Hartwig et al., 
2002) 
BER 
Fpg E.coli  activity 








 mRNA and 
protein levels,  
inhibition of the 
DNA binding 
capacity of Sp1 
transcription 
factor 
(Potts et al., 
2003; Youn et al., 
2005) 
ApeI in vitro  nuclease activity 
(McNeill et al., 
2004) 
PARP mammalian  activity 
(Hartwig et al., 
2002) 
PNK in vitro  activity 
(Whiteside et al., 
2010) 
Table 1: DNA repair proteins and its effects of cadmium intoxication. 
Cadmium exposure has been demonstrated that it inhibits the action of DNA repair 
proteins involved in different DNA repair systems 
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 1.3.4. Cadmium Toxicity and Carcinogenesis 
 Several suggestions have been made regarding how cadmium induces 
cancer; including aberrant gene expression, promotion of oxidative stress, 
inhibition of DNA damage repair and inhibition of apoptosis (Dersimonian and 
Laird, 1986). 
 In 1993, IARC concluded that there was sufficient evidence to classify 
cadmium and cadmium compounds as human carcinogens (Group 1) (IARC, 
1993). Animal studies have provided strong evidence about cadmium 
carcinogenicity, for example development of lung adenocarcinomas in rats after 
cadmium inhalation (Glaser et al., 1990; Takenaka et al., 1983). 
 
 1.3.4.1. Lung Cancer 
 Studies reviewed in (Waalkes, 2003) agree that cadmium inhalation is a 
potent pulmonary carcinogen in rats but not so much in mice or hamsters. On 
later studies, Sorahan and Esmen (2004), based on toxicological studies on 
animals and further epidemiological studies later suggested that cadmium 
compounds have different effects depending on the compound’s solubility 
(Sorahan and Esmen, 2004). The most toxic compound is cadmium chloride, for 
example, studies showed that when rats were exposed at cadmium chloride 
aerosols, they showed an increased risk of lung cancer (Takenaka et al., 1983). 
However, in another rat toxicological study it was found that other, less soluble, 
compounds mainly produced sarcomas (Klaassen, 2000; Klimisch, 1993). 
 Even though there are a few contradictions regarding human lung 
carcinogenicity of cadmium, lungs are the most well established site (Waalkes, 
2003). A study on cadmium processing workers revealed that there was 
increased lung cancer mortality for them. The chances of developing lung cancer 
were increased as the exposure intensity and duration increased as well 
(Kazantzis and Blanks, 1992). This study came in agreement with a previous one 
in which it was found that workers exposed to high levels of cadmium had an 
increased mortality risk from lung cancer (Sorahan, 1987). A cohort study on 
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cadmium-exposed workers in the US proved that there is a correlation between 
mortality from lung cancer and cadmium exposure, concluding that "the lifetime 
excess lung cancer risk at the current Occupational Safety and Health 
Administration (OSHA) standard for cadmium fumes of 100 micrograms/m3 is 
approximately 50-111 lung cancer deaths per 1000 workers exposed to cadmium 
for 45 years" (Stayner et al., 1992). Although other studies did not find great 
association between cadmium and lung cancer risk, they detected an association 
with non-malignant diseases of the respiratory system instead (Sorahan et al., 
1995). 
 
 1.3.4.2. Reproductive system cancers  
 Even though inhalation of cadmium causes lung cancer in animal models, 
ingestion of cadmium has been shown to be an effective carcinogen as well. Rats 
in particular were very susceptible to cadmium, since, ingestion of high levels of 
cadmium led to an acute hemorrhagic necrosis of the testes. On the other hand, 
ovarian cancers were shown to be dependent on the estrus cycle in hamsters. A 
very extensive and detailed review of cadmium induced cancer, after ingestion, in 
animal models and in humans, can be found in (Waalkes, 2003). 
 Moreover, several epidemiological studies have been conducted on 
dietary cadmium and its association with female reproductive cancers. However, 
there were contradictions concerning the prevalence of cadmium exposure and 
several types of cancer. Studies in Western countries showed that cadmium 
exposure correlates with an increased risk of breast cancer; an example is a 
prospective cohort study in Swedish postmenopausal women (Julin et al., 2012). 
A similar association was shown in population-based prospective cohort studies 
for endometrial cancer in Sweden (Akesson et al., 2008; Olsson et al., 2002) in 
Denmark (Larsen et al., 2002) and in the UK (Ysart et al., 1997). On the other 
hand, studies in Japan found no correlation of cadmium exposure with cancers of 
the reproductive system (Sawada et al., 2012; Itoh et al, 2013). A recent meta-
analysis have concluded that there are contradictory results, depending on 
whether the studies are based on Western and Asian populations (Cho et al., 
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2013). However in the same study it is indicated that several confounding 
factors, such as dietary habits and level of exposure, do exist and further study 
was suggested to find the underlying mechanism. 
 For the male reproductive system the given results have been 
inconsistent. An epidemiological study concluded that the mortality risk of 
prostate cancer is weakly positive even at highly exposed occupational settings 
(Sahmoun et al., 2005). Most of the studies are inconsistent, giving no clear 
results regarding the correlation between cadmium exposure and prostate 
cancer (Vinceti et al., 2007; Shigematsu I, 1982). IARC in 2012 concluded that the 
results for the prostate cancer studies showed a small association with cadmium 
exposure (IARC and WHO, 2012). 
 Finally, recent studies have indicated that cadmium could act as a steroid 
hormone, like the estrogens and androgen. The important role that hormones 
hold in reproductive system carcinogenesis gives more support to the studies 
that have associated cadmium with the reproductive system cancer. More details 
are given at the meta-analysis study of (Cho et al., 2013). 
 
 1.3.4.3. Other types of cancer 
  Recent studies have suggested that cadmium correlates with other types 
of cancers including pancreatic and renal cancers (Pesch et al., 2000; Hu et al., 
2002). However, the results have not established a clear link yet because of a few 
limitations of the studies. For example, the studies on pancreatic cancer involved 
a small number of cases and a few within an occupationally exposed population 
where other carcinogens were also present (Kriegel et al., 2006). However, a 
hypothesis has been proposed for a biological model of cadmium induced 
pancreatic cancer, because of cadmium's ability to trans-differentiate pancreatic 
cells; and therefore remains on going (Schwartz and Reis, 2000). 
 A case-control study in Canada showed an association of renal cell 
carcinoma with high cadmium exposures in males only, and the renal cell 
carcinoma risk increased as the exposure period increased as well (Hu et al., 
2002). Another case control study, although it shows an increased risk for renal 
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cell carcinoma through occupational exposure of both genders, women had the 
highest risk, as having more increased levels of cadmium in kidneys in contrast 
with men (Pesch et al., 2000). 
 
1.4. Lead 
 Lead naturally ends up in the environment from wind resuspension, sea 
salt, volcanoes, forest fires etc. (Nriagu, 1989). However, the main sources of 
environmental lead contamination and human exposure are fossil fuel 
combustion with a small contribution from cement production and waste 
disposal (Pacyna and Pacyna, 2001). Lead mainly accumulates in the upper soil in 
the form of dust with average European levels in top soil being quite 
heterogeneous around 20mg/kg; the levels could vary substantially depending 
on the distance from the pollutant source (roads, agricultural particles, and the 
concentration of non-ferrous smelters into the soil) (WHO, 2007; Salminen 
2005). Because of lead's non-degradation and strong absorbance by the soil, it 
continuously redistributes in the environment from past uses remaining in the 
soil. After 2003, lead pollution has decreased due to controls on use of unleaded 
petrol; as a consequence the main source of environmental lead has became 
metal production (Vestreng, 2005). 
 Lead is one of the most-studied metals due to on its toxicity and its effects 
on the peripheral and central nervous system. Lead also affects the reproductive 
system, liver, kidney and causes cellular toxicity. In addition, bone lead levels 
reflect long term exposure, since it accumulates there (Skerfving et al., 1993). 
Currently, lead and inorganic lead compounds are classified by IARC in Group 2B, 
possibly carcinogenic to humans, on the basis of sufficient evidence for 
carcinogenicity in experimental animals (IARC, 2006). 
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 1.4.1. Lead kinetics in human body 
 There have been various problems in the effort to estimate the correlation 
of lead exposure with blood-lead levels because of the different binding level 
with the blood cells (Skerfving, 2005). The main binding targets of lead in blood 
have been found to be the Delta-aminolevulinic acid dehydratase (ALAD) zinc 
binding sites where is binding tighter than zinc (Jaffe et al., 2001). Also, because 
it is not binding to all of the available binding sites, it inhibits the enzyme's heme 
biosynthetic activity slowly (Jaffe et al., 2001). ALAD's limited binding, explains 
the non-rectilinear relationship of lead exposure and blood levels (Bergdahl et 
al., 1997; Skerfving et al., 1993). Summarizing, it should be said that there is a 
large variety in kinetics of blood level: blood levels differ between people under 
the same lead exposure and, also, patients with the same blood levels suffer from 
different side effects (Skerfving, 2005). 
 On the other hand, there was an inverse association between lead induced 
biomarker levels in serum and in blood and renal dysfunction, which suggests 
that lead, induces an early hyperfiltration (de Burbure et al., 2006). This is 
supported by research on animal models of lead-induced renal cortex 
hypertrophy (Khalil-Manesh, 1992). Moreover, lead has the tendency to 
accumulate in the skeleton creating lead reservoirs, which could be released even 
decades after the exposure and cause endogenous exposure(Garrido-Latorre et 
al., 2002). It was found that during pregnancy the blood lead levels are increased, 
especially in lead polluted areas, while at the same time calcium levels were 
decreased. It was suggested that the mobilisation of lead from bones and 
elevated gut absorption during pregnancy could be the explanation (Lagerkvist 
et al., 1996, Rothenberg et al., 1994). The lead mobilisation from bones to blood 
could be due to various reasons. Especially during pregnancy, when the demands 
for calcium from the growing fetus is great (Pitkin, 1975, Garel, 1987), the same 
mechanism which causes calcium mobilisation from bone, also causes lead 
mobilisation (Rothenberg et al., 1994).  
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 1.4.2. Health Effects following lead exposure 
 The effects after lead exposure mostly are neurological in nature and are 
more common to fetuses and young children, because at this age neuronal 
growth and development is partially prominent. Most phenomena that interfere 
with neuronal biology have potential to leave lifetime effects. Lead has the 
tendency to accumulates in bones so later in life it could be released from there 
and cause internal toxicity. This accumulation, mainly affects mothers and 
breastfeeding children, because during that period, calcium is released to enrich 
nutrition. A brief presentation of the sensitive groups is shown at Τable 1, 
accompanied by the dangerous lead levels. The cancer sites after lead exposure 
are well established, with the bibliography generally giving consistent results at 
gastrointestinal and lung cancers (Figure 3). 
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Figure 3: Sites affected by lead exposure 
This figure shows the most commonly affected locations in the human body associated 
with lead exposure. The neurological effects of lead are very well known, affecting 
primarily children and fetuses (WHO, 2007). In addition the accumulation of lead at 
bones, leads to toxic effects in mother and infant during nursing period because of lead 
release. Animal studies have given a clear view of lead toxicity, since its effects were 
clear even at non-toxic levels, where renal carcinomas and brain tumours were 
recorded. Epidemiological studies in lead exposed workers show the validity of lead 
carcinogenesis since lung, bladder and gastrointestinal studies have been recorded (lead 
induced cancer studies in animals and humans are reviewed in Silbergeld et al., 2000; 
WHO, 2007) (adapted from Häggström, 2014). 
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 1.4.2.1. Neurological effects on children 
 Due to lead's resuspension in the air everybody may be exposed to it, 
however there are some sensitive groups, as noted from ATSDR and reviewed by 
(WHO, 2007) (Table 2). The groups at risk are mainly infants and children (WHO, 
2007). Infants receive lead through lactation from an exposed mother as the 
accumulated lead in the mother's skeleton is being released in the blood 
circulation, ending up in the breast milk (Tellez-Rojo et al., 2002). In addition, 
children that have the hand-to-mouth habit consequently ingest more lead from 
their environment than adults, something that directly affects their neurological 
development (WHO, 2007). 
 Studies conducted on children, testing their motor skills, language 
memory and learning abilities, as well as the attention and executive functioning 
gave evidence about how lead exposure affects neurological development. It was 
shown that even a low lead concentration of 3μg/dL in blood can also be 
neurologically toxic (Chiodo et al., 2004; Bellinger and Dietrich, 1994; Schnaas et 
al., 2006) not only in infants but also in children aged 6-16 who showed signs of 
cognitive effects at lead levels lower than 50μg/l (Lanphear et al., 2000). This 
indicates that there might be no threshold for lead toxicity. Also a meta-analysis 
from ATSDR (2005) has shown that also Intelligence Quotivent (I.Q.) is decreased  
1-5 points when blood lead levels were up to 10μg/dL. However, the results were 
nonlinear since at higher blood level concentrations (up to 30μg/dL) the IQ levels 
did not differ significantly compared with medium lead levels according to an 
international pool analysis study (Lanphear et al., 2005). It should also be 
mentioned that neurological effects include poor school performance, impulse 
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inhibition of ALAD, 30-300 






Decreased nerve conduction 
velocity 
200–300 
Cognitive development and 
intellectual performance 
<100 






Decreased ALAD activity 30–340 
Blood pressure <20 
Damage to renal function 
(decrease in glomerular 
filtration rate) 
20–100 
Sperm count 400–500 
Table 2: List of groups sensitive to lead exposure according to WHO. 
The sites of possible exposure of the sensitive groups are presented on this table. The 
critical levels of exposure are accompanied by the most common effects that have been 
recorded among the sensitive groups (WHO, 2007) 
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 1.4.3. Genetics and related effects 
 Although there has been over 100 years of studies on lead, all the effects 
on the biology of different organisms at the environment and cell toxicity effects 
are not clearly understood. Recent studies have shown that lead accumulates 
inside the liver and kidney cell nucleus, having clastogenic effects (Silbergeld et 
al., 2000). However, there is not enough evidence to support direct genotoxicity 
and DNA-damaging effect of lead (Skerfving, 2005), because genotoxic effects 
have been observed only at high Pb/DNA ratios in vitro (Sequaris and Swiatek, 
1991). 
 Furthermore, increased blood lead levels have been associated with 
increased Sister Chromatid Exchange (SCE), micronuclei frequency and 
chromosomal aberration giving further evidence of lead indirect carcinogenicity, 
however there is limited supportive evidence  (reviewed in Skerfving, 2005; 
Babich et al., 1985). It is assumed that lead induces genotoxicity indirectly by 
increasing sensitivity of genotoxic agents or by disabling antioxidants, thus 
reducing the redox buffering capacity of cells (Bondy and Guo, 1996). For 
example, Hunaiti and Soud (2000) have shown that incubation of whole blood 
with increased lead concentration, decreases blood glutathione levels by 40% 
and diminishes glutathione peroxidase action by 50%. In addition, lead not only 
binds to this antioxidant but also binds to histones preventing DNA protection 
(Quintanilla-Vega et al., 2000). Another example of lead correlation with ROS, it 
has been suggested that lead increases the levels of the aminolevulinic acid 
which increases the ROS levels (Hermes-lima et al., 1991; IARC, 2006). In 
addition, lead not only replaces zinc in ALAD protein structure but in several 
proteins involving in transcription reducing protein's action and it has been 
correlated with ROS generation as well (Silbergeld et al., 2000).  
  
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 28 - 
 
 
 1.4.4. Toxicity and carcinogenesis of lead 
 Several studies have been carried out on the carcinogenic effects of lead 
and the most common cancerous sites that appeared after lead exposure. 
Carcinogenicity has been associated with animals' cancer even at doses so low 
that are not toxic for organs. Rats and mice, after high lead exposure, developed 
mainly renal cortical adenomas and carcinomas and, specifically at mice, 
epithelial tumors of the renal cortex have been developed even at non-toxic lead 
doses. Another site of cancer in both animals was the brain (reviewed in 
Silbergeld et al., 2000). 
 According to one study, occupationally exposed workers in the US had an 
increased death risk from kidney cancer (Steenland et al., 1992). A few years 
later a meta-analysis was published suggesting an increased risk for stomach, 
lung and bladder cancer development but no adjustments have been made at the 
initial studies, for confounders, such as other occupational exposures, smoking 
and dietary habits (Fu and Boffetta, 1995). A study on a Swedish secondary 
smelter involving males handling mainly lead batteries, concluded that there is 
an increased mortality risk from malignant neoplasms, focusing more on the 
gastrointestinal tract (Gerhardsson et al., 1995). A different study at Swedish 
primary smelters, at which the workers have been employed for at least one 
year, has been found that although there was no increase in deaths from cancer 
in total, there was an increase in lung cancers. However, in this case workers 
were also exposed to arsenic which was not been considered at the data analysis 
(Lundstrom et al., 1997; Englyst et al., 2001). To summarise, it should be said 
that in a series of epidemiological and meta-analysis studies, lead-exposed 
workers had an increased risk of total, kidney, lung and stomach cancers. 
 Considering the findings of the studies over the years, inconsistency are 
appeared in the given results and that cancer development could be attributed to 
other coexisting metals such as arsenic and cadmium, especially in occupational 
settings. For example in a cohort study although it was found that there is an 
increased mortality risk from stomach cancer, a close association with lead 
exposure was not established. It should be noted that the non-exclusion of 
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smokers among the occupationally exposed workers and the non-consideration 
of the confounders created a false correlation between lead exposure in 
occupational settings and cancer (Wong and Harris, 2000). In addition, the 
dietary habits and the total body mass of the individuals should also be 




 Copper is an essential element for human health and it is located in a 
variety of cells and tissues. It is found at highest concentrations in liver and brain, 
where it contributes to their synthesis and proper function (Gaggelli et al., 2006; 
Turnlund et al., 1998). 
 The pathways in which copper is involved have been studied in animals 
and humans, showing that it takes part in very complicated mechanisms (Dunn et 
al., 1991; Buckley, 1991). In healthy humans, copper is present as an ion and 
combines with more than 30 enzymes and proteins, acting as a co-factor to their 
functions (Boal and Rosenzweig, 2009; Prohaska, 2008; Rosenzweig, 2001). 
These bonds between copper and the enzymes help to reduce free copper from 
participating in redox reactions and production of ROS and to deliver copper to 
specific target organs (Burkitt, 2001).  
 A normal body copper amount for a healthy male is approximately 110mg 
from which 10mg can be found in the liver, 8.8mg in the brain and 26mg in the 
skeletal muscle. Most diets contain enough copper to cover our needs without 
being at toxic levels at the same time. The recommended daily amount is 
0.9mg/d for adults with a tolerable upper limit of 10mg/d (Trumbo et al., 2001). 
 Although copper is necessary for the human body, overload or deficiency 
of copper could negatively affect health, for example by developing neurological 
diseases and atherosclerosis, hepatic and other disorders (Turnlund et al., 2004). 
It has also been associated with the production of ROS when its levels exceed the 
normal (Stern, 2010; Letelier et al., 2009).  
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 1.5.1. Copper kinetics in human body 
 Although, copper is an essential dietary component, deficiency or 
excessive intake of copper could cause several health problems. These two states, 
deficiency and excess, are difficult to be determined because of the lack of early 
biomarkers. Hair, blood and urine are used as indicators for copper toxicity but 
only big changes at copper level are detectable (Stern, 2010). 
 The absence of sensitive indicators for copper levels in human body 
makes it difficult to determine the toxic levels of it as well. So, until now, copper 
toxic effects are classified as the rare clinical diseases like the unexplained liver 
cirrhosis (Uauy et al. 2008). Researchers are still working on finding reliable and 
sensitive biomarkers with primary findings focusing at the CuZn-SOD, but there 
are concerns that the exposure of other metals could compromise the results 
(Harris, 1992). A recent study on male Wistar rats, has given promising results 
related to copper levels studying the levels of alanine aminotransferase, 
aspartate aminotransferase, triglyceride, total bilirubin and total bile acid levels 
(Yang CA, 2011). 
 
 1.5.2. Copper transport and pools 
 Copper has the potential to be toxic, thus its homeostatic mechanism in 
the human body is well maintained by intestinal absorption, biliary excretion and 
intrahepatic storage. In mammals the main target organ is the liver, which is the 
major captor, distributor and excretor of copper. Once it is absorbed, copper is 
transferred to the blood plasma where it binds predominately to metalloenzymes 
(Turnlund et al., 1998; Collins et al., 2010). Inside the cells, Golgi complex is the 
main organelle which holds the major mechanisms for copper trafficking. The 
copper-transporting Adenosine trisphotatases (ATPases), such as ATP7A and 
ATP7B, sent by the Golgi and drive copper into it. Inside the Golgi lumen, copper 
is then bound with cuproenzymes which lead copper into the secreted pathways 
(Figure 4). 
 The copper circulation in mammals starts by stomach and small intestine 
absorption by the enterocyte with the help of reductases such as the Steap2 and 
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 31 - 
 
Dyctb. Once it is reduced from Cu2+ to Cu1+, it is transferred to the cytoplasm by 
the human copper transport protein 1 (hCTR1) (Zhou and Gitschier, 1997; 
Georgatsou et al., 1997) (Figure 4A). 
 Copper transfer to newly synthesised metalloenzymes and its related 
disposal are processes driven by the same mechanism inside the enterocyte. Such 
processes are accomplished by the action of copper chaperones and by the 
copper transporting ATPases (Prohaska, 2008). For example, copper could be 
either chelated by the MT or bound to ATOX1 chaperone, which delivers copper 
to the Cu-specific transport ATPases, such as the ATP7A (Greenough et al., 2004) 
(Figure 4B). 
 After gut absorption, copper is secreted into portal circulation, at Cu2+ 
state, and binds to albumin, transcuprein or at low molecular weight copper-
histidine complexes which leads copper to other organs and tissues but mainly to 
liver (Weiss and Linder, 1985; McArdle et al., 1990; Liu et al., 2007) (Figure 4B). 
 When copper reaches liver cells, is rapidly taken into the hepatocytes by 
the same mechanism. There it binds to MT and Glutathione (GST) and acts as 
intracellular storage (Freedman et al., 1989). Copper's bond with GST could turn 
around quicker than its bond with MT, so copper becomes available for other 
services (Figure 4C). 
  At hepatocyte, the chaperone Atox1 leads copper to the Golgi network, 
trans-membrane protein ATP7B where copper binds to ceruloplasmin and is 
secreted into the blood or into the bile (Linder and HazeghAzam, 1996; Dijkstra 
et al., 1996). The part that it is excreted to the blood is primarily bound to 
ceruloplasmin (85- 90% of total Cu) that is to be transferred to tissues but may 
also be bound to albumin, transcuprein and histidine (the rest copper) (Brewer, 
2010; Harris 1993). On the other hand, the bile excretion, from the liver, is the 
main mechanism which helps the circulated copper to be eliminated from the 
human body (Aggett, 1999) (Figure 4D). 
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Figure 4: Copper mobilisation in human body. 
The important points for copper mobilisation have been marked with a star. Α) 
Following ingestion, copper is absorbed mainly by the duodenum (30- 50%) and 
partially by the stomach. B) In order for the absorption of oxidized forms of the metals to 
be accomplished, cell-surface reductases are required, such as the Steap2 and Dyctb 
reductases. The hCTR1 helps copper to get in the cytosol where chaperones, such as 
ATOX and CCS, deliver copper to various proteins and organelles; excess copper is 
sequestered by MT. C) In the hepatocyte the pathway which copper follows is the same 
except for small changes in the proteins' type, e.g. the analogous protein for ATP7A at 
the hepatocyte is the ATP7B, which pumps copper at the TGN, where copper binds to CP 
(ceruloplasmin). Copper is then released from the liver to blood circulation; in particular 
it binds to CP which delivers copper to other organs. Copper in excess is excreted to bile. 
D) Copper excreted to bile and copper that has not been absorbed after ingestion is 
discarded through faeces (adapted from Collins et al., 2010) 
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 1.5.3. Human health effects from copper deficiency 
or excess 
 A few examples of copper's role in the human body is in cellular 
respiration where the chaperone Cox17, connects copper with cytochrome c 
oxidase in the mitochondrial inner membrane (Beers et al., 1997). In addition, 
copper plays a key role in free radical scavenging, as a cofactor in the antioxidant 
enzyme, SOD (reviewed in Valko et al., 2006). It also participates in the formation 
of connective tissue with lysyl oxidase enzyme; cooperates with the transport 
agent ceruloplasmin in erythropoiesis; takes part in the formation and 
maintenance of myelin; and functions in melanin formation (Boal and 
Rosenzweig, 2009; Gaetke et al., 2014; Gaetke and Chow, 2003). 
 A very important role of copper is that it correlates positively with brain 
development and function and lack of it leads to severe neurological problems (El 
Hachimi et al., 1998). It is well understood that copper trafficking is driven by 
complicated mechanisms and several agents take part in it. Mutation at related 
transfer enzymes affects the homeostasis of copper, resulting in copper 
deficiency or overload. However copper deficiency and toxicity could occur not 
only by mutations but from a low copper intake or from large amounts of copper 
exposure as well. There is little in the literature of copper toxicity compared with 
the copper deficiency. However, it is worth stating copper deficiency effects in 
order to understand the importance of copper homeostasis mechanisms. 
 
 1.5.3.1. Copper deficiency 
 Copper deficiency is rare in adult humans; however it can be encountered 
under specific circumstances. A diet with natural nutrients deficiency, such as 
home-made baby formulas which lack sufficient copper intake, is one of them. 
Another circumstance where deficiency could occur is through pharmacological 
treatment with anti-copper drugs. Also, it can occur after surgical removal of a 
large part of the intestine. The most common effects of copper deficiency are 
bone problems such as osteopenia, a poor immune response, alterations in 
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cholesterol metabolism and impaired melanin synthesis, anemia and neutropenia  
(Olivares and Uauy, 1996; Mercer, 2001; Klevay, 2000). A last possible occasion 
could be by hereditary diseases and genetic defects, which block the functional 
action of copper, such as the Menkes disease (MD) (Brewer, 2003; Kumar and 
Low, 2004). 
 In MD, the copper excretion from the small intestine portal vein is 
blocked, leading to copper accumulation in enterocytes with a copper deficiency 
in the rest of the body. MD is an X-linked recessive inherited disorder first 
described in 1962 by Menkes, which is caused by a mutation in the ATP7A gene. 
Because of the gene's location, the severe form of the disease is noted only in 
boys with an estimated frequency of 1 in 200,000 and is diagnosed during 
infancy. Unfortunately most patients do not live beyond the third year of their life 
(Danks, 1995). 
 The health effects of MD are related to the reduced activity of 
cuproenzymes and patients having a severe clinical course. However, variable 
forms of the disease exhibit different degrees of nervous system or connective 
tissue involvement (Tumer et al., 1997). Depending on the nature and the 
number of the mutations which have been inherited, the functionality of the 
protein varies and so does the severity of the disease, since more than 40 
different point mutations have been identified (Ambrosini and Mercer, 1999). 
The clinical features which have been observed in most cases are hypo-
pigmented hair with an unusual structure. The term pili torti has been given to 
that peculiar view but it is also known as kinky or steely hair. Also, sheep with 
copper deficiency have the same look in their wool (Gillespie, 1973).  Reduced 
lysyl oxidase levels leads to abnormal collagen and elastin which leads to poor 
connective tissue structure. The main abnormalities are aortic aneurisms, loose 
skin and fragile bones. Cytochrome c oxidase is essential for energy generation 
by oxidation phosphorylation. Thus, reduced cytochrome c oxidase activity 
affects tissues with high energy demands such as the brain, the heart and the 
muscles. So, the severe neurological defects from reduced cytochrome c oxidase 
activity are very common at MD (Kaler, 1994). Despite the copper deficiency in 
the main target organs, copper tends to accumulate in other organs of the MD 
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 35 - 
 
patients such as kidney and the small intestine (Camakaris et al., 1980; Roelofsen 
et al., 2000). 
 
 1.5.3.2. Copper excess 
 Copper is released into the environment from both natural and 
anthropogenic sources, such as volcanoes and forest fires, but also from copper 
smelting, iron and steel production. Its properties, like its malleability and low 
corrosion, established it as a preferred metal for industrial purposes such as 
constructions and transportation but also in daily used sources like water pipes 
and copper cookware (Barceloux, 1999). Despite the very well maintained 
copper homeostatic mechanisms, an excess of it could occur in the human body 
after high exposure, with most frequent effects being present at the neuron 
system. The most common disease caused by copper overload, is the heritable 
Wilson's disease. 
 In contradiction to MD, Wilson's disease (WD) is caused by copper excess 
in the human body. It is caused by a mutation in the ATP7B gene inherited in an 
autosomal recessive pattern and appears in 1 in 35,000 to 100,000 people. In 
WD, enterocytes excrete copper successfully and the highest concentration is 
normally gathered at liver. Unfortunately the hepatocytes are unable to excrete 
copper to the bile, leading to a total body copper overload. The age of onset can 
vary enormously, from the second year of life to over forty (Mercer, 2001) with 
the patients exhibiting either hepatic or neurological symptoms. Patients with 
different but several mutations in both alleles have an earlier onset of the disease 
with more severe neurological problems (Thomas et al., 1995). 
 The main health effects are caused by increased copper accumulation in 
the liver as biliary excretion fails. This build up of copper leads to the death of 
hepatocytes, releasing copper to plasma. Thus, copper concentration is elevated 
in other tissues, including the central nervous system. Common observed 
characteristics of the disease are movement disorders, psychiatric disturbances, 
dementia, anxiety and disorientation (Danks, 1995). If not given an early 
treatment, death will occur by liver failure. The treatment is provided by copper 
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chelation or by oral zinc therapy (Brewer et al., 1983). Often, patients also have 
low plasma holoceruloplasmin (ceruloplasmin which carries copper) but with 
ceruloplasmin levels close to normal. 
 1.5.3.3. Cellular genotoxic effects of copper excess 
 Because copper is vital for the human body, the possible carcinogenicity of 
it has not been studied thoroughly yet, however its redox activity it is considered 
to play a role in ROS formation and thus in DNA damage (reviewed in 
Theophanides and Anastassopoulou, 2002). Several in vitro and animal studies 
have shown copper genotoxic effects such as Single Strand Breaks (SSBs) and 
SCE. It was shown in different cell cultures that cell proliferation was reduced 
and cell death frequency was increased on copper concentration and time of 
incubation dependence (Aston et al., 2000; Cortizo et al., 2004; Yang et al., 2008; 
Narayanan et al., 2001). More specifically as the time of incubation was 
increased, less copper concentration was required for the cellular effects to be 
present (Wataha, 2000). Also, copper has the ability to bind to DNA with higher 
affinity than other cations, thus promoting DNA oxidation (Theophanides and 
Anastassopoulou, 2002). Regarding animal models, a representative study 
showed that LEC rats' hepatic, renal and brain cells had deleterious effects after 
copper exposure, such as SSB (Hayashi et al., 2006). 
 
1.6. Zinc 
 Zinc is one of the most essential trace elements for the human body, since 
it contributes to several physiological mechanisms, such as DNA replication and 
transcription, and protein synthesis (Coleman, 1992; Vallee and Falchuk, 1981). 
A healthy adult contains about 2-3g of zinc in total and the daily needed amount 
corresponds at 2-3mg (Wastney et al., 1986; Stefanidou et al., 2006). Dietary 
intake of zinc is essential on a daily basis, because the human body does not store 
zinc in any tissue (Rink and Gabriel, 2000; Scott and Bradwell, 1983). 
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 The enormous size of the bibliography and the multiple mechanisms in 
which zinc is being involved cannot be covered thoroughly at this project. Thus, 
the major roles of zinc will be discussed accompanied by additional bibliography. 
 
 1.6.1. Zinc roles in cellular level. 
 Zinc is implicated in various cellular functions, for example is involved in 
the function of more than 300 enzymes and having an important role in more 
than 3000 proteins' structure as well (Maret, 2013; Takeda, 2000). The proteins, 
with which zinc interacts, are mostly involved in the immune system; however 
the function of most of them is still unknown. 
 Zinc functions can be divided into three large groups: the structural, the 
catalytic and the co-catalytic (reviewed in Rink and Haase, 2007; Rink and 
Gabriel, 2000). The role of structural zinc is to maintain the structure of the 
enzyme; however the absence of the metal ion does not affect the enzymatic 
activity (Auld, 2009). For example, zinc is a major contributor to zinc-finger 
protein's structural domains and helps the protein to fold correctly during its 
interaction with other proteins or with nucleic acids. In contrast, for the catalytic 
role, zinc participates directly in the enzyme's function, and when it has a co-
catalytic role, zinc atoms promote catalysis and sometimes stabilisation of the 
enzyme's active site. 
 In addition, zinc is a cofactor for CuZnSOD and several proteins involved 
in DNA repair. Thus, zinc plays an important role in transcription, and is also 
involved in oxidative defence and DNA repair. An extensive review of zinc's 
contribution to several cellular mechanisms is given by (Ho, 2004). 
 The list, of zinc related proteins and enzymes, is extensive, since they are 
involved in various types of mechanisms. The diversity of functional roles that 
zinc plays can be illustrated by looking at the immune system; for example see 
Table 3. 
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PROTEIN FUNCTION REFERENCES 
STRUCTURAL ROLE 
PLZF NKT cell development (Savage et al., 2008) 
Bcl-6 Proliferative expanion of germinal centers of B  
lymphocytes 
(Phan et al., 2007) 
Gfi1 T-cells lymphogenesis and pre-T-cell 
development. Differentiation of myeloid 
precursors into granulocytes 
(Karsunky et al., 
2002) 
ThPOK Necessary and partly redundant for T-cell 
differentiation 
(Carpenter et al., 
2012) 
CATALYTIC & CO-CATALYTIC ROLE 
TACE Proteolytic release from cellular membranes of 
some cytokines, chemokines, growth factors and 
their receptors, including TNF-α 
(Menghini et al., 
2013) 
Calprotectin Heterodimer forms 
Zn binding protein expressed on immune cells 




Promote chemotaxis by controlling chemokines 
activity 
Remodeling and repairing tissues 
Angio- and embryogenesis 
(Dollery et al., 1995) 
SOD-1  Anti-inflammatory activity 
Decrease of ROS 
(Marikovsky et al., 
2003) 
SOD-2 Anti-inflammatory activity 
Decrease of ROS 
(West et al., 2011) 
Table 3: Major zinc-proteins and their role in the immune system. 
A large number of zinc-enzymes are involved in the proper function of the immune 
system.  For these enzymes, zinc can be a basic structural component, a catalytic or a co-
catalytic factor. A detailed and recent review of the immune system involved zinc- 
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 1.6.2. Zinc transport and cellular pools 
 Zinc is referred to as a trace element with minor plasma ranging between 
13.8 and 22.9μmol/L. In the human body, zinc can be found in every tissue and 
fluid but most of it is found in muscles (60%), bone (30%) skin and hair (8%), 
liver (5%), gastrointestinal tract and pancreas (3%). In all other organ systems, 
zinc content is lower than 1% (Wastney et al., 1986). The largest part of 
absorbed zinc in serum is bound to proteins (98%) of which the main part is 
bound predominately to albumin and to a lesser extent to α-2- macroglobulin 
and transferrin.  Initially, it is transported to the liver and then distributed to the 
rest of the body (Haase and Rink, 2013; WHO, 2001).  Inside the cell, zinc is 
distributed among the nucleus (30-40%), membrane (10%) and cytoplasm 
(50%) (Vallee and Falchuk, 1993). The cytoplasm contains membrane-enclosed 
structures rich in zinc called zincosomes and after cell stimulation the ions are 
released.  
 Dietary zinc is primarily absorbed by the small intestine and discarded 
from the body by the pancreatic and intestinal excretion (Wang, 2010). The 
absorption of the zinc into the enterocytes happens through the apical 
membrane and then released to the circulation. Zinc transport occurs mainly 
through the two SLC (solute-linked carrier families). The one is the SLC30A 
family having the transporters proteins ZnT1-10 which transfer zinc out of the 
cytosol, whether that is out of the cell or to cellular organelles. The other family is 
the SLC39, where the ZIP1-4 proteins transfer zinc to the opposite direction 
(reviewed in Wang, 2010; Plum et al., 2010). Finally, MT play an important role at 
zinc homeostasis as the 20% of intracellular zinc binds to them. The binding 
ability of one MT molecule is up to seven zinc ions (Plum et al., 2010). 
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 1.6.3. Human health effects from zinc deficiency or 
excess 
 The benefits of zinc homeostasis are several as it contributes to growth 
and development and, at the cellular level, to proliferation, differentiation and 
apoptosis (Maret and Sandstead, 2006). Thus, highly proliferating systems, such 
as the immune, the skin and the reproductive system, will barely function under 
zinc deficiency. Its roles in the immune response, the response to oxidative 
stress, in nervous system function and also aging, are very important (Rink and 
Gabriel, 2000). Because it is involved in several pathways, zinc deficiency 
contributes to the progression of several important diseases and may complicate 
the pathology of the disease. Among these diseases are included atherosclerosis, 
several malignancies, neurological disorders, autoimmune diseases and age 
related diseases, like Alzheimer and Parkinson disease.  
 
 1.6.3.1. Zinc excess 
 Zinc toxicity could occur only under the most unusual circumstances, 
usually from excess use of food supplements or from contaminated drink, usually 
stored in galvanized units. According to WHO (2001), individuals exposed for a 
single or short time to high doses of zinc, up to 2500mg/L have exhibited nausea, 
abdominal cramping, vomiting, tenesmus and diarrhea with or without bleeding. 
Zinc toxicity induces copper deficiency and high copper excretion leading to 
copper deficiency effects which are reversible when the zinc levels are restored 
and copper is supplemented. At high ingested zinc levels as 900mg/kg it was 
found that there was a decreased absorption of copper by 40% (Hall et al., 1979). 
 Inhalation of zinc fumes has been recorded at workers, at the occupational 
setting and at soldiers from smoke bombs. Small number of soldiers had 
intoxication effects and developed adult respiratory distress symptom (ARDS). 
However, in none of the cases adequate data were given in order for zinc to be 
blamed for the respiratory effects (reviewed in Plum et al., 2010). 
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 1.6.3.2. Zinc deficiency 
 Although severe zinc deficiency is rare, mild deficiency is frequent even in 
developed countries. Deficiency of zinc can primarily occur by poor zinc diet, 
however zinc's complicated homeostasis could easily lead to zinc deficiency, if a 
mutation occurs to any of the zinc related proteins. For example, a mutation in 
the hZIP4 transporter causes a genetic disorder of zinc absorption that could be 
lethal if it is not treated (Wang et al., 2002). 
 Zinc is accumulated in the neuron cells, stored in synaptic vesicles bound 
to metalloproteins, in areas associated with transmitter release, designating the 
zinc as a possible neuromodulator agent (Smart et al., 2004). Many neurological 
and behavioral effects have been noticed in a zinc deficiency state, with slightly 
different effects being present at different developmental and age groups. The 
most sensitive were groups during developmental stages, for example infants 
and pregnant women who have higher zinc needs (Takeda, 2000). In children it 
has been associated with poor growth and retarded development, while 
behavioral tests at young monkeys showed lethargy, apathy and hypoactivity as a 
result of a poor zinc diet (Maret and Sandstead, 2006; Golub et al., 1995). 
 The early signs of zinc deficiency in the immune system are focused in the 
suppression of cells that mediate immunity. It has been shown that T lymphocyte 
function was adversely affected even in mild zinc deficiency in humans (Prasad, 
1998). Dermatitis and poor healing of cutaneous wounds could be observed 
without any other signs of zinc deficiency (Maret and Sandstead, 2006). Patients 
with elevated risk for zinc deficiency have higher possibilities for sepsis. Animal 
models showed that mice under zinc deficiency sepsis had increased possibilities 
for inflammation, increased bacterial burden, organ damage and even death (Bao 
et al., 2010). Further effects in the nervous system have been observed in animal 
experiments in which guinea-pigs showed decreased nerve conduction 
(TerrilRobb et al., 1996) and impaired neuropsychological performance 
(Sandstead, 2003). 
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 1.6.3.3. Cellular effects of zinc deficiency 
 As mentioned above, the importance of zinc in the antioxidant 
mechanisms shows the importance of zinc homeostasis, although the mechanism 
of action is not clear yet. Although in vivo and in vitro studies have shown the 
cellular effects of zinc deficiency, very little studies have been published 
regarding zinc toxicity. 
 Increased oxidative stress has been shown in zinc deficient cell cultures, 
for example the rat glioma cell line by (Ho and Ames, 2002). Also, rats' testes 
have shown DNA damage after 14 days of zinc deficient diet, proposing that the 
DNA damage has occurred by increased ROS levels (Oteiza et al., 1995). However, 
there are not more recent studies on animal studies to contribute to these 
results. On the other hand, zinc supplementation studies have given more 
evidence on zinc contribution to DNA damage. For example, zinc supplements 
protected human cutaneous fibroblasts from UVA-induced (i.e. oxidative) stress, 
DNA damage and apoptosis (Leccia et al., 1999). The correlation between zinc 
deficient diet and cancer development is not very clear yet, but there are strong 
indications for an association with prostate cancer. Further details of the 
association of zinc deficiency with DNA damage and the risk of cancer are 
reviewed in (Ho, 2004). 
  
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 43 - 
 
 Summarising, it is clear that several proteins have the ability to bind to 
metals, either contributing to the metals' homeostasis or transferring, or because 
they need the metal as a cofactor for their function. Regarding the non-essential 
metals, like cadmium and lead, details have been given of the metals' ability to 
substitute other elements at essential proteins preventing function. 
 A common characteristic between the most of these proteins is their high 
cysteine and thiol content, which is usually the binding site of the metals like for 
example the most involved with metals protein group, metallothioneins. 
 Based on this knowledge of metal-proteins' nature and the interest in 
cancer research, the Topoisomerase's vicinal cysteines were found to be of 
special interest to be studied. Based on preliminary data of Dr. S. Allinson lab 
which showed cadmium binding ability to this enzyme, further study on different 
metals that caused Topoisomerase-I inhibition was desirable to be continued. 
 Additional details on Topoisomerases are given in the following section, 
with a special focus to show the importance of further studying the protein. 
 
1.7. Topoisomerases 
 During DNA-dependent processes, such as replication, transcription, 
recombination and chromatin remodeling (Wang, 1996), the DNA strands get 
pulled apart, something that adds extra tension in both DNA sections, resulting in 
negative and positive supercoiling on each side respectively (Wang, 2002; 
Pommier, 2013). From the direction in which the helix unwinds, the supercoiling 
is positive and blocks further strand separation and therefore, polymerase 
action. Behind the polymerase, supercoiling is negative in which case the DNA is 
more relaxed than usual and contributes to the formation of abnormal nucleic 
acid structures (Pommier, 2013). 
  The enzyme family which modifies the DNA topological state is called 
Topoisomerase. According to their mechanism, Topoisomerases are divided into 
two types: Τype I and II (Figure 5). Type-I enzymes create SSBs to the DNA with 
no need for ATP energy, whereas Type-II enzymes create double strand breaks 
and are ATP-dependent (Champoux, 2002). Topoisomerase-I (Topo-I) is further 
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sub-divided into Topoisomerase-IA and Topoisomerase IB (Wang, 2002). 
Topoisomerase-IB  binds to the 3' phosphate with the DNA and relaxes both 
positive and negative supercoiling (Champoux, 2002). In contrast, 
Topoisomerase-IA binds to the 5' phosphate of the hydrolysed DNA, relaxing only 
positive super-coiling with the requirement of a pre-existing nicked substrate 
and Mg ions (Champoux, 2001). There are three classes of Topoisomerase-I 
enzymes which are classified as IB type.  These are all of the Topoisomerase-I 
enzymes which have been found in eukaryotes, the poxvirus Topoisomerases 
(vaccinia enzyme) and the prokaryotic Topoisomerase-V from Methanopyrus 
kandleri (Slesarev et al., 1994; Slesarev et al., 1993; Pommier et al., 2010). 
 Topoisomerases have been found in prokaryotes and eukaryotes, and also 
in some viruses, and are essential for viability (Wang, 1996; Champoux, 2001). 
For example, knockout models in mice (Morham et al., 1996) and in Drosophila 
melanogaster (Zhang et al., 2000) showed that the Topoisomerase-I enzyme is 
essential for DNA nuclear division, cell proliferation and thus the oogenesis and 
the progression of the development. However, similar knockout experiments in 
yeasts showed that they can survive, but with genomic instability, as 
Topoisomerase-I can be substituted by Topoisomerase-II (Christman et al., 1988; 
Uemura and Yanagida, 1984). In addition, human cell lines were created with 
stabilised knockdown Topoisomerase-I, where only 10%-20% of normal 
Topoisomerase-I were expressed. Proving the importance of normal 
Topoisomerase-I, those cells showed spontaneous genomic alternations, the 
replication has been affected and also gene expression has been altered (Miao et 
al., 2007). Additionally, Topoisomerase-I is involved in the regulation of 
transcription and the activation of splicing factors  (Merino et al., 1993; Soret et 
al., 2003; Pommier et al., 2010).  
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Figure 5: Classification of human Topoisomerases. 
Topoisomerases which have been identified in humans are mainly classified as Type-I 
and Type-II. The molecular masses have been calculated from polypeptide composition 
(kDa) and the (x2) refers to dimers. Type IA enzymes are the only enzymes that relax 
only positive but not negative supercoiling. However, Type-IB and Type-IIA can both 
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 1.7.1. Topoisomerase-I structure and mechanism 
 Topoisomerase-I is a monomeric, bi-lobed protein that wraps completely 
around the DNA forming a temporary phospho-tyrosine bond with one end of the 
nicked DNA strand (Stewart et al., 1998). Human Topo-I is approximately 91kDa 
and consists of four sub-domains (Stewart et al., 1996; Champoux, 1998) (Figure 
6). The first is the 24kDa N-terminal domain which consists of 214 amino acids. 
Then, it is the 56kDa core domain which consists of 421 amino acids and is 
further subdivided into the core subdomains I, II and II. A small linker domain 
around 7kDa and 77 amino acids connects the core domain with the 6kDa C-
terminal domain of 53 amino acids, that contains the active-site tyrosine residue, 
Tyr 723 (Stewart et al., 1996). It has been shown that the enzyme is active and 
functional even after the removal of the N-terminal and the linker domain, where 
the core domain and the C-terminal mixed form a 1:1 complex (Stewart et al., 





Figure 6: Domain structure of Topoisomerase-I structure. 
Regarding the structure of the Topoisomerase-I domains first is the N-terminal domain, 
followed by the core domain. A small linker domain connects the core domain with the 
C-terminal domain. The numbers over the rows indicate the number of the amino acids 
in which the domain starts and ends. The core and C- terminal domains are highly 
conserved and they contain most catalytic residues. Specifically C- terminal domain 
contains the active site of Topoisomerase-I, Tyr 723.  
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  The two lobes of the enzyme are connected via an α-helix that belongs to 
the sub-domain III and is called 'connector' (Champoux, 2001). On the opposite 
side, a salt bridge and six amino acids create a connection between the cap and 
the base of the protein creating the 'lips' of the protein (Stewart et al., 1998), 
which allows it to open and close during the active period, as it creates space for 
DNA movement (Redinbo et al., 2000). The linker domain is located at the base of 
the protein (Figure 7). 
 During its active phase, the Topoisomerase encloses the DNA and its 
interacting domains turn the DNA, and the tension is relieved. The one lobe of the 
protein comprises the core's sub-domains I and II, which clamp the DNA, where a 
long α-helix creates a V-shaped form, the so called 'cap'. The second lobe of the 
protein, also known as the base, consists of the core sub-domain III and the C-
terminal (Redinbo et al., 1998). The C-terminal is composed of five short α-
helixes and the active residue Tyr-723. It also interacts with the core sub-domain 
III, by three α-helixes, belonging to the sub-domain III. This interaction creates "a 
solvent-accessible surface" as it was described by (Redinbo et al., 1998) (Figure 
7). 
 Several amino acids co-operate in clamp formation around the DNA, such 
as Arg 488, Lys 532, Arg 590, and His 632 (Figure 6). However, Tyr-723 is one of 
the most crucial amino acids as it breaks the phosphodiester bonds of the DNA 
and forms a temporary covalent bond with the 3' end of the cut DNA. This bond 
does not allow the strand break to reconnect (Figure 8) (Wang, 2002; Champoux, 
2001). The formation of the covalent bond results in a single strand break and 
the enzyme rotates the complex in the absence of cofactors and releases the 
break. In this way, DNA is relaxed by having one less twist (Stewart et al., 1998).  
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Figure 7: Topoisomerase-I topological state. 
The Topoisomerase-I wraps around the DNA as the C-terminal nicks and connects with 
the DNA, while the rest part the enzyme hugs the DNA helping the unraveling of the 
DNA. Cap: At the upper side we can see the cap of the enzyme, which is consisted of the 
core sub-domains I (yellow) & II (Blue). Because of the lack of a full length protein 
reconstitution, the N- terminal is represented where it was supposed to be, at the 
beginning of the core sub-domain I. Base: At the opposite side, we can see the base of the 
enzyme, consisting of the C-terminal (green) and the core sub-domain III (red). Lips: 
Three residues of each sub-domain, I and III, and a salt bridge connect the enzyme from 
this side, forming the so-called 'lips'. Connector: the connector composing by a α-helix, 
belonging to the sub-domain III connects the two lobes opposite the lips of the enzyme. 
Linker: The linker domain protrudes from the main enzymes formation, being attached 
between the two domains, C-terminal and Sub-domain III, of the 'base'. The linker 
domain is not necessary for the topoisomerase function (adapted from Champoux 2001). 
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Figure 8: Topoisomerase I mechanism of action. 
A) The annealing of the DNA, causing the DNA supercoiling, slowing down the cell 
machineries (e.g. replication, transcription, chromatin remodeling). B) Topoisomerase-I 
binds to the DNA, via its active site, by making a SSB. By making a control rotation, 
Topoisomerase relax the DNA. The action is completed by the religation of DNA. C) The 
chemical structure of the enzyme's active site bonding with the DNA (adapted from 
Pommier, 2006a). 
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 1.7.2. Topoisomerase-I cleavage complexes and its 
inhibitors 
 The complex of Topoisomerase-I with the DNA is called the 
Topoisomerase-I cleavage complex (Topo-I-cc), which is the target of 
pharmacological Topoisomerase-I inhibitors. Although these complexes are often 
formed throughout the genome, the religation procedure is very rapid, making 
them difficult to be detected. This characteristic is the one that makes the 
Topoisomerase-I inhibitors so unique because they have the ability to detect the 
Topo-I-ccs and bind to them, ceasing the procedure on this particular point 
(Pommier, 2006a).  
 In the case that Topo-I-ccs will be stabilised, cell death could occur. There 
are three possible ways in which the stabilisation could take place; the first one is 
that the ccs could be trapped by drugs such as camptothecin and its derivatives 
(Pommier et al., 2003). A second mechanism is DNA modifications which prohibit 
DNA religation activity by Topoisomerase-I, such as misalignment of the 5′ end of 
the nicked DNA creating a damaged DNA. The third one is the possible DNA 
and/or Topoisomerase-I modifications that occur during programmed cell death 
(apoptosis) (Pommier, 2006b; Pourquier and Pommier, 2001). In fact, 
Topoisomerase-I inhibitors are cited as having a wide range of antitumor 
activities and are among the most widely used anticancer drugs clinically 
(Sunami et al., 2009; Seng et al., 2010) 
  
 Camptothecin (CPT) is a cytotoxic plant alkaloid isolated from the Chinese 
tree Camptotheca acuminata that have been used in traditional Chinese medicine. 
CPT was first isolated in 1958 by Wall et al. and structurally elucidated a few 
years later (Wall et al., 1966; Tang et al., 2006) (Figure 9). Because of its property 
to block DNA and RNA synthesis it was tested in Western countries for 
pharmacological purpose in the 1970s as an anticancer agent (Hsiang et al., 
1989). Although CPT gave promising results on cancer treatment in mice, such as 
solid tumors, breast, lung, and colorectal cancer, it gave also quite a few side 
effects, such as leucopenia, vomiting and diarrhea (Wall and Wani, 1995; 
Soepenberg O, 2003). CPT creates reversible lesions by binding to the 
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Topoisomerase-I-DNA complex (Hsiang et al., 1985). It has been suggested that it 
does not bind directly to either the enzyme or to the DNA, but to the complex of 
enzyme-DNA (Hsiang et al., 1989; Hsiang et al., 1985; Hertzberg et al., 1989). 
Using X-ray crystallography to explore the Topo-I and DNA complex, a theory has 
been born that explains the CPT interaction with Topo-I-DNA complex. It 
suggests that CPT interacts with the DNA at the cleavage site, intercalating into 
the DNA and preventing DNA religation (Redinbo et al., 1998). After binding, the 
created CPT-Topo-I complex renders the enzyme unable to ligate DNA SSBs, 
which have been produced, causing its anti-cancer activity (Pommier, 2006a). 
 Since it was discovered that Topoisomerase-I is the target of CPT, many 
studies have been conducted to find other inhibitors which could bind at a 
different cellular stage or that could stabilise the cleavage complexes in a 
different DNA sequence so the cellular effects will vary. Examples of those 
inhibitors are the indolocabazoles and the phenantroline derivatives and lots of 
them continued in clinical development from the early 90s (Yamashita et al., 
1992; Long et al., 2002). Indenoisoquinolines are another Topo-I inhibitors and 
several of its derivatives have also been selected for clinical development 
(reviewed in Pommier, 2006a; Pommier et al., 2010). Boswellic acids and other 
pentacyclic triterpenes, such as the betulinic acid (BA) are also Topo-I inhibitors, 
with inhibitory efficacy comparable to CPT. In contrast to CPT, BA inhibits Topo-I 
cleavage rather than religation ability, thus is considered as Topo-I inhibitor 
instead of toxic agent (Syrovets et al., 2000). Different derivatives have been 
found to be cytotoxic to cancer cells, such as acetyl-BA on human leukemia cells 
(HL-60) (Shao et al., 1998) and BA to human melanoma, neurodermal tumours 
and leukemia L1210 cells with the latter being in pre-clinical stage (Pisha et al., 
1995; Fulda et al., 1997; Noda et al., 1997).  
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Figure 9: Binding of camptothecin to Topoisomerase-I and DNA. 
The molecular structure of CPT binding with the Cytosine and the amino acids Asp 533 
and Arg 364 of Topoisomerase-I. 
(is granted to be used for any purpose, without any conditions) 
(page URL: https://commons.wikimedia.org/wiki/File%3ACamptothecin_binding.svg) 
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1.8. Aim of study 
 Summarising the literature of metals' toxic effects and their ability to 
disrupt enzymes' action, it has been considered essential to study the inhibition 
of Topoisomerase-I. Studies on Topoisomerase-I are limited regarding its 
interaction with metals. The initial and only study of metals ability to bind with 
Topoisomerase-I has been conducted by (Stewart et al., 1996) in which high 
concentrations of nickel, zinc, copper, cadmium and cobalt (5mM) were able to 
inhibit the enzyme. Preliminary work at Dr. Sarah's Allinson lab (unpublished 
data) has shown that cadmium could inhibit the Topoisomerase-I in more 
physiological concentrations. The aim of this study is to test the toxicity of more 
metals validating the existing literature, adding information for metals' toxicity 
levels and proposing a novel mechanism, by which these metals act and form 
carcinogenesis. It is worth saying that carcinogenesis is an accumulation of 
genetic and epigenetic aberrations by affecting DNA repair and protection 
mechanisms. Thus, the understanding of the metal induced carcinogenicity will 
be an additive knowledge at the molecular bases of carcinogenesis in general 
offering hope for the creation of better chemotherapeutic drugs in the future. 
 Firstly, clonogenic assays were applied at human lung fibroblast MRC5 
cell line and also immunofluorescence assays were applied testing the induced 
levels of the histone γH2AX, as a DNA damage marker. Secondly, the metals' 
ability to inhibit the enzyme Topoisomerase-I in more physiological 
concentrations was tested during cleavage and relaxation experiments, in 
contrast with Stewart et al. (1996) where it was tested only the relaxation ability 
of the enzyme in higher concentration. Lastly, the Topoisomerase-I expression in 
bacteria and mammalian cells was attempted. Previously, the expression of the 
protein was completed successfully in Baculovirus infected cells again by Stewart 
et al. (1996). However, a successful expression of the protein in more easily 
manipulated cells will open new doors for novel results at the mechanism of 
action of metal induced carcinogenesis. 
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2. MATERIALS AND METHODS 
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 In this section all the used materials such as, metal compounds, buffers 
(Table 4), solutions and antibodies (Table 5) are described. All chemicals have 
been obtained from Sigma-Aldrich unless otherwise stated. Metals were used in 
the dichloride form (i.e. M2+Cl2) and purchased from Sigma-Aldrich. The metal 
solutions were prepared in deionised water in 100mM stock and further 
dilutions were made from that stock throughout the project 
 
STOCK SOLUTION COMPOSITION/ PROVIDER 
BSA 10mg/ml (New England Biolabs) 
EDTA 0.5M pH 8.0 
FA/SDS 10 mM EDTA, 98% formamide, 1% SDS, 10 mg/ml blue 
dextran 
Incision buffer 10x 100 mM Tris pH 7.5, 500 mM NaCl, 50 mM MgCl2 and 1 mg/ml 
BSA 
PBS  10mM Phosphate (as sodium phosphates), 2.68mM Potassium 
Chloride (KCl), 140. Sodium Chloride (NaCl) 
Reaction buffer (5x)  0.1 M Tris, 1 M NaCl, 10% glycerol, 5mM DTT 
Relaxation assay stop 
buffer 
3% SDS, 30% glycerol, 30mM EDTA, bromophenol blue 
RIPA buffer 50mM Tris pH 8.0, 150mM NaCl, 1% I Gepal CA-630, 0.5% 
Sodium deoxycholate, 0.1% SDS, completed with a Mini-EDTA 
free protease-α inhibitor tablet (Roche) and with a 
Phosphatase tablet inhibitor tablet (Roche) 
SDS 3x 150 mM Tris-HCl (pH 6.8), 300 mM DTT, 6% SDS, 0.3% 
bromophenol blue, and 30% glycerol 
TAE 50x 2000mM Tris, 1000mM Acetic acid, 50mM EDTA 
TBE 10x 890mM Tris, 890mM Borate acid, 20mM EDTA 
TE 1 M Tris pH 7.5, 1 μM disodium EDTA(0,5Μ), pH 8.0. 
TGS 10x 250 mM Tris 1.92 M glycine, 1% SDS 
Topo-I dilution buffer 10μΜ Tris pH 7.5, 1μΜ DTT, 50% glycerol, 100μg/ml BSA 
Urea gel 25% acrylamide (19:1 acrylamide/bisacrylamide), 8M Urea 
Urea gel buffer 5x 5x TBE 250ml, 8M urea 
Table 4: The composition of the buffers 
All the buffers which have been used throughout this project are presented in this table. 
The dilution level is described in each section respectively. 
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Table 5: List of antibodies 
The antibodies are divided on the basis of their classification as primary and secondary 
antibodies. In addition, the working concentrations of the antibodies are provided. 











Mouse Ab to gammaH2A.X 
[9F3] phospho S139 
1:3000 ABCAM ab26350 











Alexa Fluor 488 goat anti-mouse, 
IgG (H+L) 
1:1000 INVITROGEN 1008719 
Sheep pAb to Mouse IgG (HRP) 1:2000 ABCAM ab26350 
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2.1. Cell culture 
 MRC5 (human lung fibroblast) and HeLa (human cervical carcinoma) cell 
lines were grown in a 37oC incubator with 5% CO2. The growth medium was 
DMEM (Lonza) supplemented with 10% fetal bovine serum and 100U/ml 
Penicillin and 100μg/ml Streptomycin (Lonza). Before each experiment, the cells 
were grown to 80% confluence, washed in PBS, trypsinised in 1x trypsin-EDTA 
(0.5g/L trypsin, 0.2g/L EDTA) (Lonza) and resuspended in 10ml  of pre-warmed 
fresh medium. 
 
 2.1.1. Clonogenic survival assays  
 The cell concentration was counted in hemocytometer and 250 cells were 
seeded in a 60mm dish, containing 4ml DMEM medium in total. The cells were 
incubated for 3 hours to allow them to attach and were then treated with the 
heavy metals for 24 hours, at increasing concentrations indicated in the results 
(Section 3.1.). 
 Afterwards, each cell culture was washed with PBS and 3ml of fresh pre-
warmed medium were added and incubated for 7 days. Before the cell staining, 
the medium was removed and then the cells were washed twice with 2ml PBS. 
70% ethanol was then added for 10 minutes for cell fixation. Giemsa stain (Sigma 
Aldrich) was added at a 20-fold dilution in each dish for 30 minutes and the cells 
were washed carefully with water before cell colonies were counted (Figure 10). 
Then the % survival was calculated as the fraction of colonies formed relative to 
an untreated control. 
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Figure 10: Schematic representation of clonogenic assay 
1) MRC5 cells were left to grow at T75 flasks until they have reached 80-90% 
confluence. Then, the cells were washed and trypsinised (in 1x trypsin-EDTA). 2) 250 
cells were seeded in 60mm dishes and incubated for 3 hours. 3) The cells were treated 
with the metals for 24 hours. 4) After the treatment the cells were washed with PBS and 
medium replaced with a fresh one in which the cells were incubated for 7 days. 5) The 
cells were fixed with 70% ethanol and stained with Giemsa at 20-fold dilution, so the 
colonies could be counted. 
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 2.1.2. Immunofluorescence assay of γ-Η2ΑΧ 
formation 
 In a six-well plate 1x105 cells were seeded per well with a cover slip in the 
bottom of each well. After incubation for 24 hours, the cells were treated with 
metals or zeocin at concentrations described in the Results (Section 3.2.). The 
cells were incubated with either metal for 24 hours or zeocin for 1 hour. 
Afterwards, the wells were washed with 2ml of PBS and 2ml of 4% PFA (Santa-
Cruz Biotechnology) was added for 20 minutes at room temperature for cell 
fixation. Then the cells were washed carefully with 2ml of PBS three times and 
2ml of 0.5% Triton X-100 (Sigma- Aldrich) in PBS added for 10 minutes to 
permeabilise the cells which were then washed again three times with 2ml PBS. 
 For the antibody blocking first, the cover-slips were covered with 200μl of 
3% BSA (Sigma- Aldrich) for 1 hour at room temperature and were washed three 
times with PBS. The primary antibody for γH2AX (table 5) was diluted in 3% BSA 
(Table 4) and 200μl of the antibody solution covered each cover-slip for 1 hour at 
room temperature, followed by five washes in 200μl of PBS for 5 minutes each. 
The secondary antibody, Alexa Fluor 488 goat anti-mouse (Table 5) was diluted 
in 3% BSA and 200μl of the dilution covered the cover-slips for 1 hour at room 
temperature. Then, each cover-slip was washed five times with PBS before 
mounting on a slide with Vectashield with 4',6-diamidino-2-phenylindole (DAPI) 
(Vectorlabs). The experiments were repeated three times. 
 Pictures were taken using fluorescence microscopy using Zeiss 510 Meta 
Confocal Scanning Microscope. A mean of three images were taken per sample 
each portraying three nuclei. The data from the images were collected using the 
program ImageJ and the mean intensity per pixel was calculated, out of three 
experimental repeats. Briefly, the mean intensity was calculated by dividing the 
integrated density of the pixels from the selected areas (nucleus) by the total 
number of pixels in that area. 
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2.2. Western blot 
 2.2.1. Sample preparation 
 For the Western blot sample preparation, the cell lysate were isolated as 
described in the according sections followed (Section 2.4.1. and 2.5.4.). Then, SDS 
was added and the samples were boiled at 95oC, for the denatured form of the 
protein to be stabilised. 
 
 2.2.2. Samples running and transferring 
 The samples were run in a 4-15% precast SDS-polyacrylamide gel: Mini-
PROTEAN TGX Precast Gels (Bio-Rad). The gel were loaded and run for 30 
minutes at 200V along with the molecular weight marker, Precision plus Protein 
All Blue Standards (Bio-Rad). The tank was filled with 1x TGS running buffer.    
 Afterwards, the samples were transferred under 25V and 1.3A for 7 
minutes using the Thermo Scientific Pierce G2 Fast Blotter, following the 
manufacturer's instructions. The PVDF membrane, in which the samples were 
transferred, had a pore size of 0.45μl (Immobilon-P). The sandwich of the gel 
/membrane was wetted with the 1-Step Transfer Buffer (Thermo Scientific). 
 
 2.2.3. Antibody Blocking 
 First the membrane was blocked for one hour in 5% powdered skimmed 
milk (Marvel) in TBST and the appropriate primary antibody was mixed with 1% 
milk in TBST and incubated with the membrane for 1 hour on a rotator at room 
temperature. Then the membrane was washed three times in TBST for 5 minutes. 
The appropriate secondary antibody was added in 1% milk at the suggested 
dilution followed by five washes in TBST for 5 minutes each. Afterwards, the 
blocked membrane was exposed to ECL Plus Western blotting reagent (Thermo 
Scientific) and the results were visualised on a Biorad Chemidoc system. 
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2.3. Topoisomerase inhibition by heavy metals 
 2.3.1 Topo-I substrate preparation 
 The substrate was an oligonucleotide labeled with the 3' fluorophore 
ATTO647 (Eurofins Genomics) and having a known Topo-I cleavage site. The 
single strand oligonucleotide was diluted in TE buffer (Table 4) in a way to have 
a 100μM final concentration. In order to make a dsDNA, 10μl of the substrate was 
mixed with 12μl of the Topoisomerase-I-reverse oligonucleotide in 1:1.2 
concentrations (Table 6). Sodium chloride (NaCl) 200mM was added for the 
dsDNA stability and the sample was heated to 95oC and allowed to slowly cool 




3'-ATTO647 labelled CAAAGTCAGGTTGATGAGCATATTTTACTCATAAG 
Reverse GTTTCAGTCCAACTACTCGTATAAAATGAGTATTC 
Table 6: The 3'labelled oligonucleotide substrate and the reverse oligonucleotide. 
The mix of those two oligonucleotides in 1:1.2 concentration formed the working 
substrate of the double-stranded DNA. 
 
 The dsDNA was mixed with 6μl of 50% glycerol and was loaded on an 8% 
non-denaturing acrylamide gel (Table 7). The gel was pre-run in 1x TBE buffer 
(Table 4) at 120V for 30 min, at which point the samples added and subject 
electrophoresis at 120V for 90 minutes, to purify the substrate. 
 The band containing the double stranded substrate; was cut out from the 
gel carefully and put in an eppendorf tube with 300μl TE buffer and stored 
overnight at 4oC. Ethanol precipitation followed in order to isolate the purified 
DNA. Using a Spin-X centrifuge tube filter (Costar) the gel, containing the dsDNA, 
was centrifuged in a micro-centrifuge at 13.000rpm for 3 minutes to separate 
liquid from gel. Sodium acetate buffer solution at 3M concentration (pH 5.2) was 
added to the samples in the one ninth of the total sample volume followed by 
three volumes of 100% ethanol. The samples were left in -80oC for 20 minutes 
followed by a spin at 13.000 rpm for 10 minutes. The supernatant was discarded 
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and the pellet was washed with 200μl of 70% ethanol and subsequently 
centrifuged for 2 minutes. The pellets were left at 37oC to dry completely. The 
DNA was dissolved by adding 10mM Tris (pH 7.5) and the DNA concentration 




Accu gel 19:1 (40% w/v) 10ml 
T.B.E.  5ml 
10% APS  250μl 
TEMED 25μl 
Deionised water up to 50ml 
Table 7: 8% non-denaturing acrylamide gel. 
The ingredients were mixed and poured in between glass plates (20cm x 16cm) with 
1.5mm spacers, where the gel was allowed to set. The gel was pre-run in TBE buffer for 
30 minutes. 
 
 2.3.2. Substrate titration 
 The prepared substrate was titrated in order to estimate the optimum 
substrate concentration for detection. The substrate was prepared at five 
different dilutions, given in the results (Section 3.3.1.1.), and run in a 20% 
denaturing PAGE gel (Table 8).  The gel was pre-run at 42W for 90 minutes 
followed by electrophoresis of the loaded samples for 150 minutes at 42W. The 
result was visualized on a Typhoon 9410 imager.  
 
COMPONENTS CONCENTRATION 
Urea Gel 40ml 
5x urea gel buffer 10ml 
10% APS 250μl 
TEMED 25μl 
Table 8: 20% denaturing PAGE gel. 
The buffers which are listed in this table were mixed thoroughly, poured between glass 
plates with 0.4mM spacers and the gel was allowed to set. The gel was allowed to pre-
run at 42W for 90 minutes. 
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 2.3.3. Topoisomerase-I enzyme titration 
 The Topoisomerase-I enzyme which was used for the experiments 
(Section 2.3.4. and 2.3.5), was a wild type hexa-histidine-Tagged human 
Topoisomerase-I, purchased from Calbiochem. The enzyme was titrated in order 
to identify the minimum concentration that gave the optimum activity, which 
was 0.625μg/ml final concentration. The enzyme was diluted in dilution buffer 
(Table 4) to five different concentrations. The final composition of the other 
components in these reactions was 10mM Tris (pH 7.5), 50mM NaCl, 5mM 
MgCl2, 1μM CPT, 0.1mg/ml BSA and 2.5nM substrate. 
 The reactions were initiated by addition of the Topoisomerase-I enzyme 
in five different concentrations, as described in the results (Section 3.3.1.2). The 
samples were mixed and incubated at 37oC for 1 hour. The reactions were 
stopped then by addition of an equal volume of FA/SDS (Table 4), and heated at 
95oC for 3 minutes. Then the samples were run in 20% denaturing PAGE gel 
(Table 7). 
 
 2.3.4. Topo-I oligonucleotide cleavage assay 
 The aim of this experiment was to see which metals inhibit the cleavage 
action of Topo-I. The reactions were composed of 10mM Tris (pH 7.5), 50mM 
NaCl, 5mM MgCl2, 1μM CPT, 0.1mg/ml BSA and 0.625μg/ml enzyme. 100μM of 
the metals were added to the reactions and an additional negative control was 
prepared containing water instead. The reactions were left at 4oC for 5 minutes 
to allow the enzyme to interact with the metal and then the reactions were 
initiated by adding the substrate at 2.5nM final concentration. Incubation at 37oC 
for 1 hour was followed and the reactions were stopped by adding an equal 
amount of FA/SDS (Table 4) and heated at 95oC for 3 minutes. The samples were 
run in a 20% denaturing PAGE gel (Table 7). The results were visualized at a 
Typhoon-9410 fluorimager and the percentage of inhibition was calculated. The 
calculations briefly included the division of the % intensity of product per 
reaction by the % intensity of product of the control sample, which showed the 
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full enzyme activity per experiment, and all subtracted from 1 and multiplied by 
100. The % intensity of product was estimated by the division of the intensity of 
the product per reaction by the intensity of the whole oligonucleotide (product 
and substrate intensity), multiplied by 100. 
                   
                                     
                                       
      
                         
                                   
                             
      
                                                                          
 
 2.3.5. Topoisomerase-I relaxation assay 
 The supercoiled pBR322 plasmid (Inspiralis cat.# S2502) was supplied in 
buffer containing EDTA, to avoid the EDTA complexing with the metals being 
tested. Therefore, before use, the EDTA was removed using a GeneJet PCR 
purification kit according to the manufacturer's instructions and eluting into 
10mM Tris pH 8.0. 
 The reaction consisted of the 5x reaction buffer, 20mM Tris, 0,2M NaCl, 
2% glycerol, 1mM DTT, 0.1mg/ml BSA, 0.625μg/ml of the Topo-I enzyme and the 
metals in concentrations detailed in the results section. All components were 
mixed and left on ice for 5 minutes. The reaction was started by the addition of 
1μl plasmid DNA (0.5mg/ml), the solution was mixed well and incubated at 37oC 
for 15 minutes. The reaction was stopped by adding 6μl of stop buffer (Table 4). 
A no-enzyme control was also prepared which contained all the previously 
mentioned components; however, the reaction was prevented as stop buffer was 
added before the plasmid DNA. 
 Samples were run in a 1% agarose gel, at 120V for 75 minutes in 1x TAE 
buffer (Table 4). The gel was post stained with 1μg/ml ethidium bromide buffer, 
for half an hour and visualized using the GelDoc imager (Biorad). 
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2.4. Topoisomerase I expression in bacteria 
 2.4.1. Transformation of bacteria with plasmid is 
induct of protein expression 
 The SoluBL21 (Genlantis cat.# C700200) and the Arctic Express (Agilent 
cat.# 230192) host strains of competent E.coli, were transformed with the vector 
pET28-derived plasmid vector (see Appendix E), pETTop1H. The plasmid 
contains a kanamycin resistance gene and the open reading frame of C-terminally 
His-tagged Topo1 under the control of the highly efficient promoter T7 (Novagen 
cat.# 69864-3). The pET plasmid is transformed into genetically modified 
bacteria which express the T7 RNA polymerase under control of the lac 
promoter. Thus, stimulation of the bacteria with the galactose analogue Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) leads to the expression of the T7 polymerase 
and the translation of the gene of interest encoded by the plasmid. 
 The following procedure was applied for the bacteria transformation; 
10ng of the vector was added to each of the competent cells and were left for 30 
minutes on ice. Then the cells were heat shocked by incubation for 30 seconds at 
42oC and immediately placed on ice for 2 minutes. Afterwards, into the cell-
vector mixture 250μl of SOC medium were added and incubated at 37oC for 1 
hour.  Afterwards, each transformation reaction was spread on an LB agar plate, 
which was supplemented with 30μg/ml of the antibiotic kanamycin. Following 
an overnight incubation at 37oC a single colony was isolated from each plate and 
was resuspended in 5ml LB growth supplemented with kanamycin at 30μg/ml 
final concentration and left overnight in a shaking incubator at 37oC. 
 The bacterial growth and the sample collection described for each host 
strain separately, in order to point out the few differences at the procedure. 
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SoluBL21host strain growth and sample collection  
 To a 50ml culture of LB kanamycin at 30μg/ml were added and 500μl of 
the cell culture and incubated for 3 hours (i.e. to mid-log phase) at 37oC. Then, 
1ml of the culture was centrifuged in a micro-centrifuge at 6000rpm for 5 
minutes and the pellet was resuspended at a 200μl of 1x SDS and heated for 3 
minutes at 95oC and the sample was stored. In the meanwhile, the rest of the 
culture was supplemented with IPTG at 1mM final concentration and incubated 
for an additional 3 hours. Every 60 minutes, 1ml was removed from culture and a 
sample was prepared as described above. 
 
Arctic Express host strain growth and sample collection 
 The same procedure was followed for this cell line, as described above for 
the SoluBL21, but with a few modifications. The cell culture was allowed to cool 
down on ice before adding the IPTG and an additional sample was collected after 
an overnight incubation at 37oC.  
 
 The collection of the samples was designed to see the successful 
increasing levels of the Topo-I protein after the inactivation of the lactose 
repressor. After the sample collection the samples were stored at -80oC. The 
samples were run on an SDS page gel and stained with Instant blue dye. In 
addition, a Western Blot was applied as described at Section 2.2. blotting with 
anti-Topo-I and anti-hexa-histidine-Tag antibodies. 
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2.5. Topoisomerase I expression in mammalian 
cells 
 2.5.1. Preparation of vector 
 The pZeoSV2-derived plasmid (see Appendix E) pZeoTOP1H was 
transformed into NEB Turbo competent E.coli (New England Biolabs, cat.# 
C2984). The vector contained the open reading frame of C-terminally hexa-
histidine-Tagged Topoisomerase-I, under the control of the SV40 enhancer/ 
promoter. 50μl of the bacteria were mixed with 0.5μl (100ng) of the plasmid and 
left on ice for 30 minutes before heat shock at 42oC for exactly 30 seconds. 200μl 
of SOC outgrowth medium were added into the transformation mixture and then 
incubated for 1 hour at 37oC. After the incubation, volumes of 50μl and 200μl 
bacteria were spread on separate Petri dishes with Low Salt Medium agar 
containing Zeocin at 25μg/ml. Plates were incubated overnight in an incubator at 
37oC. 
 A starter culture was made by collecting a single colony of the 
transformed bacteria described in section 2.5.1., inoculated into 5ml low salt 
medium supplemented with 25μg/ml zeocin, and was incubated for 8 hours in a 
37oC shaking incubator. The starter culture was diluted at 1/500 into selective 
Low Salt medium containing zeocin and the bacteria were left to grow for 16 
hours in a 37oC shaking incubator before harvesting by centrifugation. The 
plasmid DNA was purified from the E.coli bacterial pellet following the protocol 
from (QIAGEN plasmid midi kit). At the end of the purification the DNA 
concentration was estimated using a spectrophotometer at 260nm. 
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 2.5.2. Transfection of mammalian cells 
 The purified plasmid DNA was transfected into HeLa cells and the 
expression of the hexa-his-Tagged Topoisomerase-I protein was tested with a 
Western Blot. The HeLa cells were grown into 4 T75 flasks and when they 
reached 80% confluence the medium was removed and the cells were washed in 
10ml PBS. Afterwards, the cells were trypsinised in 5ml trypsin-EDTA (1x), 
divided into two 15ml centrifuge tubes and 5ml fresh pre-warmed medium 
(DMEM) were added to stop trypsinisation. The cells were collected by 
centrifugation for 5 minutes at 500 g. The supernatant was discarded followed by 
a second centrifugation for 2 minutes in order to remove all the liquid from the 
cells. 
 The transfection was completed using the Amaxa cell line Nucleofector Kit 
R (Lonza) following the kit instructions and the procedure was carried out in 
duplicate, one for the plasmid DNA, pZeo TOP1H (section 2.5.1) and one for the 
pmaxGFP vector. The pmaxGFP vector is a plasmid encoding green fluorescence 
protein (GFP) under the control of the CMV promoter and was used as a positive 
control in parallel with the pZeo TOP1H. Briefly, 100μl of the transfection reagent 
was mixed with either the pmaxGFP vector or with the pZeoTOP1H at 500μg/ml 
final concentration. The cell pellets were re-suspended carefully in these mixes 
and were transferred into electroporation cuvettes. The transfection was 
completed by electroporation using the I-13 program for Hela cells from the 
Nucleofector I Device (Lonza). After the transfection was completed, the cells 
were dispensed into 100mm plates and incubated for 24 hours. Pictures of the 
fluorescence from cells were taken from Zeiss Axiovert 35 epifluorescence 
microscope using the Zen lite software and the successful transfection to be 
visualised. The images for the pmaxGFP vector green fluorescence were taken 
using the long pass LP520 and the light source for the pZeoTopo-I vector was the 
HBO100 mercury lamp (white light). 
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 2.5.3. Purification of His-Tagged protein from 
transfected mammalian cells 
  The purification of the His-Tagged Topo-I protein from the transfected 
mammalian cells was undertaken using the QIAexpressionist protocol (QIAGEN). 
Briefly, the procedure includes the following steps. 1) Transfected cells were 
washed with 10ml PBS and collected by centrifugation for 5 minutes at 1000g. 2) 
The cells were then resuspended in 500μl of lysis buffer (50mM NaH2PO4, 300 
mM NaCl, 10mM imidazole, and 0.05% Tween 20 (pH 8.0)). 3) The cells were 
lysed by sonication on ice and the cellular debris was collected as pellet by 
centrifugation for 10minutes at 1000g at 4oC. 4) 5μl Ni-Nta magnetic beads were 
then added to each cleared lysate and the mixture incubated at 4oC for 1-2 hours 
on an end-over shaker. 5) With the help of a tube magnet the supernatant 
removed and the beads washed with wash buffer (50mM NaH2PO4, 300mM Na-
Cl, 20mM imidazole, 0.05% Tween (pH 8.0)) at least for 3 times, 1 minute each. 
6) At the end of the washes 50μl of elution buffer (50mM NaH2PO4, 300mM NaCl, 
250mM imidazole, 0.05 Tween 20 (pH 8.0)) were incubated with the beads for 
one minute and then the eluate was collected. 
 At each washing step the solution was kept for SDS-PAGE analysis to 
ensure that no Topoisomerase-I was released from the beads. A Western Blot 
was applied to the final eluate (Section 2.2.), but also to all kept samples during 
the purification, blotting with anti-Topo-I antibody (Table 5). 
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3.1. Clonogenic assay of MRC5 cells treated with 
cadmium, lead, zinc and copper 
 In order to see the effects of heavy metals on human lung fibroblast, MRC5 cells 
were treated with cadmium, lead, copper and zinc in five different 
concentrations. Lung cells were used as a model because lung is the primarily 
exposed tissue of industrial fumes and dust. The cells exposed with the metals for 
24 hours and then incubated for 7 days without metal. The % survival and the 
L.C.50 of the metal were estimated based on colony numbers. For cadmium, lead 
and copper the cells were treated with metal concentrations of 200μM, 100μΜ, 
50μΜ, 25μΜ and 12.5μΜ. On the other hand, zinc is an essential trace element 
and higher concentrations were therefore needed in order for toxic effects to be 
seen. It should be mentioned that medium contains zinc ions, but in 
concentrations are in order of magnitude lower than those tested and were not 
considered. Cells were therefore treated with zinc in the following 
concentrations; 400μΜ, 200μΜ, 100μΜ, 50μΜ and 25μΜ. A no metal control was 
present for each experiment and all conditions were carried out in triplicate for 
each experiment, with each experiment also being replicated three times. 
 Cadmium was the metal with the highest toxicity on MRC5 cells, as the 
L.C.50 was approximately 15μM, with a lower survival in comparison with the 
rest of the metals. A sharp decrease in the number of colonies appeared after 
treatment with very low cadmium concentrations until 25μM. A plateau was 
reached after the 50μM of cadmium where only a few colonies were apparent. At 
the two higher metal concentrations of 100μM and 200μM no colonies had grown 
(Figure 11). 
 The cells treated with lead showed survival decreased by 50% at a 
concentration approximately 66μM. The MRC5 cell's survival decreased as the 
concentration increased. In Figure 12, the steady downward trend of the survival 
can be seen, reaching the highest metal concentrations of 200μM where only a 
few colonies were apparent. The results could indicate that longer exposure to 
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the metal may be needed in order to reach more toxic effects regarding the cell 
survival.  
 Regarding copper and zinc, both gave L.C.50 of about 55μM. Copper 
showed a sharp decrease in cell survival until 50μM, followed by a less 
pronounced decrease in the number of colonies to 200μM of copper. Even at the 
highest concentration there were a few colonies remaining in every repeat of the 
experiment (Figure 13). On the other hand, zinc showed a big gap at cell survival 
among the no treated with the 25μM treated cells, reaching the level of the 40% 
decrease of the colonies. However, a very small survival difference has been 
noted between the 25μM and 50μM treated cells with the latter reaching very 
close to the 50% of the survived cells. There were almost no surviving colonies in 
the highest concentration of 200μM (Figure 14). 
 
 Concluding, cadmium is the metal with the highest toxicity and is more 
lethal for the MRC5 cells, as the L.C.50 was approximately 15μM. Zinc and copper 
follow with a L.C.50 approximately at 55μM.  In acute short exposure lead was 
the least toxic, where greater than 65μM of lead was required in order for half of 
the cell population to be killed. 
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Figure 11: Clonogenic survival of human lung fibroblasts treated with cadmium. 
MRC5 cells were treated with cadmium in the indicated concentrations for 24 hours 
(Section 3.1). Colonies were then allowed to grow for 7 days and the % survival was 
calculated by dividing the number of counted colonies by the colonies of the untreated 
control. Points represent the mean of three independent replicates and the standard 
deviation is shown. 
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Figure 12: Clonogenic survival of human lung fibroblasts treated with lead. 
MRC5 cells were treated with lead in the indicated concentrations for 24 hours (Section 
3.1). Colonies were then allowed to grow for 7 days and the % survival was calculated by 
dividing the number of counted colonies by the colonies of the untreated control. Points 
represent the mean of three independent replicates and the standard deviation is shown. 
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Figure 13: Clonogenic survival of human lung fibroblasts treated with copper.  
MRC5 cells were treated with copper in the indicated concentrations for 24 hours 
(Section 3.1). Colonies were then allowed to grow for 7 days and the % survival was 
calculated by dividing the number of counted colonies by the colonies of the untreated 
control. Points represent the mean of three independent replicates and the standard 
deviation is shown. 
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Figure 14: Clonogenic survival of human lung fibroblasts treated with zinc. 
MRC5 cells were treated with zinc in the indicated concentrations for 24 hours (Section 
3.1). Colonies were then allowed to grow for 7 days and the % survival was calculated by 
dividing the number of counted colonies by the colonies of the untreated control. Points 
represent the mean of three independent replicates and the standard deviation is shown. 
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3.2. Immunofluorescence assay of γH2AX 
 3.2.1. The role of histone H2AX in the DNA repair 
mechanisms  
 In eukaryotic cells the DNA is wrapped around histone groups, consisting 
of five main histone proteins that organise the eukaryotic DNA into chromatin, 
the H1, H2A, H2B, H3 and H4 families. H1 acts as a linker between nucleosomes 
with the DNA being wrapped round a histone core octamer, composed of two 
copies of each of the remaining four histone types (Foster and Downs, 2005). The 
H2A histone has three subfamilies the H2A1-H2A2, the H2AZ and the H2AX 
where the latter represents 2-25% of the H2A complement in normal fibroblasts, 
but this ratio is dependent on the cell type  (Rogakou et al., 1998; Bonner et al., 
2008).  
 Rogakou et al. (1998) for the first time identified the phosphorylation of 
H2AX in the presence of double strand breaks (DSBs) created by ionising 
radiation. In the presence of DSBs H2AX histone close to the DNA break is rapidly 
phosphorylated by PIKKs (phosphatidyl-inositol-3-kinase-related kinases). This 
phosphorylated form of H2AX is called γH2AX and is considered a marker of DNA 
damage. It is a rapid but also sensitive marker by being present in very low levels 
of irradiation (Rogakou et al., 1998). Within seconds following DSB formation, it 
spreads to kilobases of DNA around the break site and contributes to the DNA 
repair procedure (Celeste et al., 2003). It is phosphorylated as a result of both 
double and single strand breaks but especially by DSBs (Kuo and Yang, 2008). 
 The number of induced DSBs corresponds to the number of the nuclear 
domains, called foci, which γH2AX forms per cell. Those foci areas can be 
visualised using fluorescence microscopy (Rogakou et al., 1998). In order to 
study the formation of DNA damage by heavy metals, a monoclonal anti-γH2AX 
antibody (Table 5) was used to detect the phosporylated form of H2AX, as a 
marker of DNA damage, measurable by immunofluorescence (Figure 15). The 
metals used for this thesis were cadmium and lead at 50μM final concentration, 
zinc at 125μM and copper at 200μΜ each incubated for 24 hours with MRC5 
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cells. Also, zeocin has been used as positive control at 50μM treating the metals 
for 1 hour. Zeocin is able to produce an increased amount DSBs in a short period 
of incubation so it suitable to be used as a positive control agent. 
 At this project, the immunofluorescence detection of γH2AX did not show 
any significant difference between the metals, apart from lead which showed an 
induced phosphorylation of twice that of the rest of the metals.  Figure 16 shows 
the mean intensity per pixel taken from all the experimental repeats. As we can 
see there is a great difference in the pixel intensity density between Zeocin and 
the metal treated cells. A slightly greater density above the control was evident 
only for lead. A statistical analysis using a t-test showed statistical significant 
results (p-value < 0.01) implying that all of the metals can induce the 
phosphorylation of the histone H2AX to γH2AX, although in different extent 
though. 
  
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 79 - 
 
 
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 80 - 
 
Figure 15: Metal induced low levels of γH2AX formation 
MRC5 cells were treated with cadmium (50μM), lead (50μM), copper (200μM) and zinc 
(125μM) for 24h. For creating positive control samples the cells were treated with the 
zeocin (50μM) for 1 hour. Also a negative control has been used in order to have an 
immediate comparison of the level that γH2AX was formatted. Here we see 
representative pictures taken from each metal treatment in the following order: positive 
control, negative control, cadmium, lead, copper, zinc. Each image is divided in three 
parts and from left to right we see the fluorescence from the Alexa-Fluor 488-conjugaled 
secondary antibody (Table 5); then is the nuclei with DAPI and the third part shows the 
merged image. 
  
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 







Figure 16: The pixel intensity of the cell nuclei probed with anti-γH2AX antibody 
after metal exposure. 
This graph represents the mean intensity per pixel after metal exposure, of three 
experimental repeats, expressing the level H2AX phosphorylation. The standard 
deviation of the produced data is shown from the error bars. The generation of data 
arose by using the program ImageJ and the mean intensity per pixel was calculated. The 
cells were exposed to the indicated concentrations of metals for 24 hours or of zeocin for 
1 hour. A mean number of three nuclei were measured per image and a total number of 
three images were taken per sample at each experiment. The asterisk declares the 
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3.3. Inhibition of Topo-I function 
 Topoisomerase-I poisons stabilise the cleavage complexes between Topo-
I and DNA. At the present project the level of Topoisomerase-I inhibition from 
cadmium, lead, zinc and copper was measured through cleavage and relaxation 
assays. A reaction of the Topoisomerase-I, either with a linear dsDNA or with a 
supercoiled plasmid DNA, was initiated. The results were visualised due to either 
the conjugated fluorophore after exposure to the fluorescent compound 
Ethidium Bromide, as described in the material and methods, Section 2.3.1 & 
2.3.5., respectively. A previous study has shown the inhibitory effects of high 
(non-physiologically relevant) levels of heavy metals, cadmium, copper, cobalt 
and zinc, at Topoisomerase-I function (Stewart et al., 1996). High exposure in 
those heavy metals usually arises from occupational setting or from a polluted 
environment (water, plants and animals). However, individuals are exposed in 
those metals in everyday life due to dispersion of dust. Thus, the human health 
effects from the metal exposure in more physiological levels would be good to be 
tested. The following experiments show the inhibition of topoisomerase-I, in 
reactions where heavy metals were present. Preliminary, unpublished data from 
our lab shows that cadmium inhibits Topoisomerase-I in low metal 
concentrations (Dr S. Allinson), so the remaining metals were of importance to be 
tested as well.  
 The cleavage and relaxation functions of Topoisomerase-I were tested by 
a co-incubation with cadmium, copper, nickel, lead, zinc and cobalt in 
concentrations ranging from 1.56μM to 100μM. As reaction substrates an 
oligonucleotide labeled with the fluorophore ATTO647 (2.5nM) has been used at 
the cleavage assay and the supercoiled plasmid pBR322 (0.5mg/ml) in the 
relaxation assay. It should be mentioned that the substrate of Topo-I cleavage 
site can be increased by the presence of CPT in the reaction buffer (Table 4). 
 In the cleavage assay the expected result was that Topoisomerase-I will 
nick the DNA in recognised position, giving a smaller product. Under metal 
presence, it was expected this nicking activity to be potentially inhibited by the 
metal binding to the enzyme's active sites, preventing its normal action. In the 
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relaxation assay the enzyme was expected to relax the supercoiled plasmid used 
for substrate. Thus, a floppy and slower migrating form of the DNA would be 
created in contrast with the condensed structure of supercoiled DNA, which was 
expected to be seen if the enzyme is inhibited by the metals. 
 
 3.3.1. Topoisomerase-I oligonucleotide cleavage 
assay 
 The Topo-I oligonucleotide cleavage assay principle is that the incubation 
of a labeled substrate, that has a Topo-I binding sequence, with the Topo-I 
enzyme will give a band after a denaturing polyacrylamide gel electrophoresis 
(figure 17). The reaction is stopped and the cleavage complex is blocked before 
the DNA will be rejoined. Using denaturing PAGE gel and a fluorimager the size of 
the labeled band could be detected. The cleaved oligonucleotide, being smaller in 
size, runs further in the gel in comparison with the long length of the full 
oligonucleotide. 
 Several drugs like CPT have the ability to bind to the enzyme and inhibit 
its religation ability. According to previous studies (Stewart et al., 1996) and to 
preliminary data from Dr. S. Allinson, heavy metals can inhibit the 
Topoisomerase too. Thus, depending on the size of the product the level of the 
Topoisomerase inhibition of the metals could be seen. 
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Figure 17: The principle mechanism of the oligonucleotide cleavage assay. 
A) The full oligonucleotide with the ATTO647 label B) During the incubation of the 
labeled substrate with the Topo-I, the enzyme cleaves the oligonucleotide. At this step 
the experiment was stopped and the level of nicked DNA was able to be measured by 
urea- electrophoresis. The no nicked oligonucleotide is much longer than the cleaved 
one and stays much higher after the electrophoresis. 
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 In the present study, the metals cadmium, copper, nickel, lead, zinc and 
cobalt in 100μM final concentration each, were incubated for 1 hour with 
0.625μg/ml Topo-I enzyme reacting with 2.5nM of the oligonucleotide substrate. 
A reaction with no metal was used as a control to calculate the percentage of 
inhibition, since the control reaction shows the full enzyme-oligonucleotide 
interaction. An image of the results was taken using a Typhoon-9410 
fluorimager. However, in what follows, first the results of the substrate and the 
enzyme titration are given, because these provided a basis for all the following 
experiments. 
 
 3.3.1.1. Substrate preparation and titration 
 The double stranded substrate was prepared by mixing equal 
concentration of the indicated substrate and the complementary 
oligonucleotides, as described in 1:1 concentration, and after the gel purification 
the concentration of the mix was 5.46μM estimated by spectrophotometry at 
260nm. 
 Previously in our lab TAMRA fluorophore has been used instead of the 
ATTO647. Thus, it was essential to determine the optimum substrate 
concentration that could be detected, using the Typhoon fluorimager. It has been 
demonstrated that different fluorophores attached to the same oligonucleotide, 
can give dramatically different results, underlining the importance of initial 
characterization of the substrate for successful measurements (Anderson et al., 
2008). The concentration of the substrate used at concentrations started from 
the 25nΜ and was diluted four times in 1:10 each, with the lowest concentration 
being 2.5pM (Figure 18). The final concentration of the substrate chosen to be 
used subsequently in reactions was 2.5nM, because it has reasonable sensitivity 
and in the case that we will get a 10% cleavage product, the product will still be 
readily detectable. 
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Figure 18: The substrate titration for cleavage assay. 
Five different concentrations of the dsDNA substrate were prepared. The lanes 1 to 5 
represent the different concentrations of the substrate per reaction. The different 
substrates concentrations were loaded at the lanes in the following concentrations: lane 
1) 2.5pM, lane 2) 25pM, lane 3) 0.25nM, lane 4) 2.5nM, lane 5) 25nM. The samples were 
analysed following electrophoresis on a non-denaturing acrylamide gel. 
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 3.3.1.2. Topoismerase-1 enzyme titration 
 Titration was required for the Topoisomerase-I enzyme (Calbiochem) as 
well, in order to see the minimal amount of enzyme required for the substrate 
concentration. Thus, five different dilutions have been applied to the original 
0.5mg/ml stock of enzyme, starting from 1:100 up to 1:1600 dilutions (Figure 
19). Since all gave detectable products, the concentration of 0.625μg/ml was 





Figure 19: Topo-I enzyme titration. 
Five reactions have been prepared containing different enzyme concentrations. At the 
reaction loaded at lane 1 were 0.31μg/ml; at lane 2, 0.625μg/ml; at lane 3 1.25μg/ml; at 
lane 4, 2.5μg/ml and at lane 5 were 5μg/ml at the final reaction volume. 
  
LANCASTER UNIVERSITY, 2014-2015 
HEAVY METAL TOXICITY IN HUMAN LUNG FIBROBLASTS AND INHIBITION OF 
HUMAN TOPOISOMERASE-I AS A POTENTIAL MECHANISM 
- 88 - 
 
 3.3.2. Topoisomerase-Ι cleavage function inhibition 
by heavy metals  
 The metals which totally inhibited the Topo-I activity in concentration of 
0.625μg/ml were cadmium, copper and zinc, as no cleavage product was 
detectable. Partial inhibition of the enzyme was visible for the remaining metals: 
nickel, lead and cobalt. A representative image is shown in Figure 20 (see 
Appendix A for all three experiments). The metals' concentration was 
subsequently titrated, in order to see the range of concentrations at which each 
metal inhibited the enzyme (Figures 21, 23, 25).  
 The findings of the metal induced Topo-I enzyme inhibition, were 
followed by titration of every metal. Only the metals, which induced complete 
inhibition at 100μM, were titrated. The substrate and enzyme concentrations 
were kept constant as in the previously described experiment. Titrations of 
cadmium, copper and zinc were only carried out to determine the range of 
concentrations in which these metals are able to inhibit Topo-1 function. Every 
metal was diluted eight times starting from 50μM and stopping at 1.56μΜ of final 
concentration in each reaction. Once more a no metal control was used as a 
measure of uninhibited Topo-I activity. The results were visualised and the data 
were collected on the Tuphoon-9410 fluorimager followed by the calculation of 
the percentage of inhibition as described in the materials and methods' Section 
2.3.4. 
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Figure 20: Topoisomerase-I cleavage function inhibition by heavy metals. 
The metals indicated were added in the reactions at 100μM and incubated with the 
presence of the 0.625μg/ml enzyme and 2.5nM of substrate for 1 hour at 37oC. The 
experiment was repeated three times. The non reacted substrate and the product of the 
reaction are shown with arrows. 
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 3.3.2.1. Cadmium titration in Topo-I cleavage assay 
 The cadmium titration showed that it is able to inhibit Topoisomerase 
activity even in very low concentrations. A band of the product becomes obvious 
at 1.56μM of cadmium but Topo-I was still partially inhibited. The experiment 
was repeated three times giving consistent results. A representative image is 
shown in Figure 21 (see Appendix B for all three experiments). 
 The percentage of the inhibition is expressed by a graph (Figure 22) 
which shows that even at very low cadmium concentration, as 1.56μM, Topo-I 
activity has a mean inhibition of 50%. At higher concentrations the inhibition of 
the enzyme ranges from 87% inhibition and higher. Even though the error bar is 
large at the lower cadmium concentration, the least inhibition is still seen at 
1.56μM. 
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Figure 21: Topoisomerase-I cleavage activity inhibition by cadmium 
Cadmium was added to the reaction in different concentrations and incubated with the 
enzyme for 1 hour at 37oC. The experiment was repeated three times. From left to right 
the samples are shown first the no metal control followed by the titrated cadmium 
concentrations of 1.56μM, 3.125μM, 6.25μM, 12.5μM, 25μM and 50μM. The substrate 




Figure 22: Bar graph of the cadmium titration at Topoisomerase cleavage activity. 
This graph shows the percentage of inhibition of Topo-I cleavage activity by different 
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 3.3.2.2. Copper titration at cleavage assay 
 When copper was titrated into the cleavage assay, an unusual effect was 
observed as the enzyme was inhibited in the lowest concentration of 1.56μM but 
not at the two next lowest concentrations of 3.125μM and 6.25μM. At 12.5μM of 
copper in the reaction there was a partial inhibition of the enzyme. A 
representative image is shown in Figure 23 (see Appendix C for all three 
experiments). After the calculation of the percentage inhibition there was a 
significant negative value of the % inhibition of the product at the 3.125μM and 
6.25μM of copper, suggesting a stimulation of the enzyme. It could be assumed 
that in this concentration the copper is contributing to enzyme's activity at the 
oligonucleotide. Considering the large variation in the results which is showed by 
the large error bars, this effect may not be real. However, the enzyme was 
inhibited by 90% under the presence of 50μM and 25μM of copper at the 
reaction at all the three repeats (Figure 24). 
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Figure 23: Topoisomerase-I cleavage activity inhibition by copper. 
Copper was added to the reaction in different concentrations and incubated with the 
enzyme for 1 hour at 37oC. The experiment was repeated three times. From left to right 
the samples are shown first the no metal control followed by the titrated copper 
concentrations of 1.56μM, 3.125μM, 6.25μM, 12.5μM, 25μM and 50μM. The substrate 




Figure 24: Bar graph of the copper titration at Topoisomerase cleavage activity. 
This graph shows the percentage of inhibition of Topo-I cleavage activity by different 
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 3.3.2.3. Zinc titration at cleavage assay 
 The titration of zinc showed a linear decrease in Topo-I inhibition with 
decreasing concentration of zinc. A cleavage product was visible at 
concentrations below 12.5μM of zinc. However, the product intensity gradually 
decreased as the zinc concentration increased. Also, in the concentration of 
1.56μM an apparent stimulation of the enzyme was observed as the intensity of 
the product was higher than the control. A representative image is shown in 
Figure 20 (see Appendix D for all three experiments). On the graph the 
percentage of the enzyme's inhibition by zinc is described. The enzyme 
stimulation it could be seen also on the graph at the 1.56μM, indicating that the 
zinc might have a role of the enzyme binding to the DNA (Figure 26). The 
experiment was repeated three times giving consistent results for the trend 
between metal concentration and inhibition. However the percentage inhibition 
was different between experiments at the medium and low concentrations which 
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Figure 25: Topoisomerase-I cleavage activity inhibition by zinc. 
Zinc was added to the reaction in different concentrations and incubated with the 
enzyme for 1 hour at 37oC. The experiment was repeated three times. From left to right 
the samples are shown first the no metal control followed by the titrated zinc 
concentrations of 1.56μM, 3.125μM, 6.25μM, 12.5μM, 25μM and 50μM. The substrate 
and the product of the reaction are shown with arrows. 
 
 
Figure 26: Bar graph of the zinc titration at Topoisomerase cleavage activity. 
This graph shows the percentage of inhibition of Topo-I cleavage activity by different 
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 3.3.3. Plasmid relaxation assay 
 The relaxation assay is based on the topological state of the DNA after 
incubation with the enzyme. The compact structure of the supercoiled plasmid 
means that it migrates further through the gel whereas the relaxed plasmid, 
which has a more flexible, open structure, migrates behind the supercoiled DNA 
when they are run in an agarose gel (Figure 27). As it is known, human Topo-I 
has the ability to relax supercoiled DNA so the level of function of the enzyme 





Figure 27: The principal mechanism of the plasmid relaxation assay. 
A) Representation of the supercoiled plasmid pBR322, which were used in the 
experiments. Supercoiled plasmid DNA runs faster in agarose gel electrophoresis than 
relaxed plasmid DNA. The Topo-I binds to the DNA, nicks it and relaxes it. B) The relaxed 
form of the DNA after the Topo-I contribution. Thze relaxed form is much slower in an 
agarose gel electrophoresis. C) Depending on the position of the plasmid DNA at the gel, 
the form of the DNA could be recognised and the level of Topo-I action could be 
estimated 
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 Supercoiled plasmid pBR322 was used to test the level of Topo-I 
inhibition under the presence of heavy metals. As in the cleavage assay, the 
metals which were used in the initial relaxation assay were cadmium, copper, 
nickel lead, zinc and copper at a final concentration of 100μΜ and incubated with 
0.625μg/ml of the enzyme at 37oC for 15 minutes. Two controls were used in this 
experiment a positive and a negative for inhibition. The positive control had no 
enzyme in the reaction so the supercoiled form of the plasmid could be 
compared. The negative control for the inhibition did not have metal during the 
reaction, so the full enzyme activity could be seen.  
 A representative image is shown in Figure 28, where cadmium, copper, 
lead and zinc gave positive results for the inhibition of the Topo-I. Supercoiled 





Figure 28: Inhibition of Topoisomerase-I relaxation activity. 
The metals indicated were added at 100μM final concentration and incubated with 
0.625μg/ml of Topo-I. The relaxed and the supercoiled form of the plasmid DNA are 
indicating at the right side of the figure. 
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 3.3.4. Relaxation assay metal titration 
 Among the metals which were used, the ones that inhibited plasmid 
relaxation by Topoisomerase-I, at 100μM, have been titrated. Thus, it could be 
seen, for each, in which concentration the Topoisomerase-I reaction was not 
disrupted by the metals. The metals that were used were cadmium, lead, copper 
and zinc in concentrations ranging from 50μM down to 1.56μM, in 2-fold dilution 
steps. The reaction was initiated by the addition of Topo-I enzyme at 
concentration 0.625μg/ml. The reaction condition was the same as at the 
previously described initial relaxation experiment.  
 A positive correlation was found between the titration of cadmium in the 
plasmid relaxation assay and in the cleavage assay (Figure 21). As we can see 
below, cadmium inhibited the Topo-I plasmid relaxation even in concentrations 
as low as 3.125μM (Figure 29A). At 3.125μM of cadmium there was a small 
difference in the intensity of the band, which may indicate that there was slightly 
less super-coiled DNA. Between 3.125μM and 1.56μM we saw a dramatic change 
of inhibition level as in the lowest metal concentration there was no detectable 
inhibition at all. 
 When lead was titrated in the plasmid relaxation assay, it was found that 
the plasmid was fully relaxed from 6.25μM of the metal and lower 
concentrations. In the three highest (50μM, 25μM and 12.5μM) concentrations of 
lead, was a progressive increase in the amount of relaxed plasmid as the metal 
concentration decreases. The enzyme activity was fully inhibited in lead 
concentrations from 50μM to 12.5μM in contrast with the lower concentrations 
were the DNA showed to be fully relaxed (Figure 29B). 
 In comparison with the results obtained for cadmium, the titration of 
copper into the relaxation assay did not correlate well with the results obtained 
in the cleavage assay. More specifically full inhibition was observed only in the 
highest metal concentration of 50μM. In the other concentrations the plasmid 
was fully relaxed (Figure 29C) 
 Titration of zinc into the plasmid relaxation assay gave fully relaxed 
plasmid DNA in concentrations of 12.5μM and below (figure 29D). In 
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concentrations of 50μM and 25μM of zinc there was partial inhibition, as the 
supercoiled band was not so intense as the positive marker for the inhibition. In 
addition intermediate bands of incompletely relaxed DNA were seen between the 
main bands of the relaxed and the super coiled DNA, particularly in higher 
concentrations of zinc. The titration of zinc showed partial inhibition of Topo-I 
activity at 50μM and 25μM. The lower concentrations caused no detectable 
inhibition and the enzyme was able to relax the supercoiled DNA fully. 
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Figure 29: Titration of metals Topo-I into plasmid relaxation assays. 
From left to right first is given the positive control (no enzyme) and the negative control 
(no metal) followed by the reactions with the titrated metal. The co-presence of Topo-I 
and metal in different concentrations was at the following lanes. The metal used in each 
experiment is indicated at the top left side of each image at the following concentrations 
50μM, 25μM, 12.5μM, 6.25μM, 3.125μM and 1.56μM. The positions of the supercoiled 
and relaxed DNA are indicated on the right side of the figure.  
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3.4. Bacterial expression of recombinant human 
Topo-I 
 Experiments on Topo-I, were carried out so far using commercially 
available Topo-I. However, in order to further investigate the metal-dependent 
inhibition of the enzyme and in particular the potential role of various cysteines 
in mediating this inhibition, it was necessary to establish a recombinant source of 
Topo-I that could be manipulated. Previous attempts to express human Topo1 in 
Escherichia coli (Bronstein et al., 1999) have been unsuccessful; however, the 
newer generation of BL21-derived expression strains may allow successful 
expression providing an in vivo approach to increasing the yield of soluble 
protein produced in E.coli. 
 The used bacterial cell strains were the SoluBL21 and the Arctic Express 
strains are derived from the BL21 strain which enables them to express high 
levels of protein, through T7 RNA polymerase under the control of the lac 
repressor. SoluBL21 is an improved mutant strain which could increase 
efficiently the protein solubility and the expression levels of toxic proteins; 
however the exact reason is not clear. Arctic Express cells co-express cold-
adapted chaperonins from the bacterium, Oleispira antarctica, which allow the 
strain to confer improved protein processing at lower temperatures with the aim 
to increase the yield of soluble protein (Dyson et al., 2004).  
  The coding sequence of C-terminally hexa-his-Tagged Topo-I under the 
control of the T7 promoter had already been cloned into the pET28 vector prior 
to the start of this project. This plasmid was transformed into the two above 
described strains SoLuBL21 and to Arctic Express and the expression of Topo-I 
was tested since its expression was controlled by the lactose promoter. The cells 
were treated with the IPTG to induce upregulation of T7 RNA polymerase and 
harvested after 1, 2, 3 hours and overnight incubation, as described in the 
materials and methods' section 2.4.1. The protein lysate from each sample was 
run through an SDS-PAGE gel subsequently stained with Instant Blue dye for 30 
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minutes. A Western Blot was also carried out to establish Topo-I cross reacting 
bands. 
 Topo-I has a predicted mass of 90kDa. After Instant Blue staining a band 
of that size was faintly present with increasing intensity during the incubation 
time following addition of IPTG. However, the contrast of the larger band above 
does not allow us to see it clearly. The same pattern of bands was present in both 
cell strains with the only difference being that the 90kDa band in the Arctic 
Express cell line was only visible after overnight incubation (Figure 30). In order 
to confirm that this protein is a full length human topoisomerase I a Western Blot 
was applied by specifically blotting with anti Topo-I and anti His-Tag antibodies. 
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Figure 30: Test expression of the Topo-I BL21-derived strains 
The samples were loaded on an SDS-PAGE gel and stained with an Instant Blue dye. On 
the left side of the figure is shown the total protein of the SoLuBL21 cells incubated at 
37oC at variant time points before and after IPTG addition to the culture of 1, 2 3 hours . 
The same pattern is repeated on the right side of the image, using the Arctic Express cell 
line incubated at 37oC and lowered on by put on ice before the IPTG addition. The 
samples taken were the same depending the incubation time, with an additional sample 
taken following overnight incubation. MWM: the molecular weight marker is shown on 
the very left side of the figure having a size range of 10- 250kDa. Topo-I molecular size is 
marked with an arrow on the right side, at 90kDa. 
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 Although with the Instant Blue staining there was a clear indication of 
Topo-I expression, a Western Blot was carried out to confirm the identity of the 
protein. The anti-Topo-I antibody blotting showed a protein of the correct size 
and several cross-reacting products of smaller size. Some of these were only 
detectable in the samples taken following IPTG induction and could be products 
resulting from either protein degradation or from incomplete translation (Figure 
31A). There were also non-specific products which were present even before the 
IPTG addition to the culture. These can be attributed to bacterial cross-reacting 
proteins. The presence of the C-terminal hexa-his-tag allowed more specific 
blotting, as it would only be present in fully translated products. If the smaller 
fragments detected with anti-Topo-I antibody, were due to incomplete 
translation, then, they would not cross-react with an anti His-tag antibody. 
However, proteolytic cleavage would mean that some of the smaller 
Topoisomerase-I fragments might be expected to cross-react. 
 The blotting of the His-Tagged end of the Topo-I (Figure 31B) gave only a 
30kDa cross-reacting band that was also present in the uninduced control. 
Because signal was received also at samples were the IPTG was not present, the 
products were characterised as non-specific. Due to the presence of incomplete 
Topoisomerase-I fragments and the inconclusive results for the His-Tag blotting 
it was decided to discontinue this approach. Instead, an attempt was made to 
express the protein in mammalian cells. 
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Figure 31: Bacterial expression of His-Tagged Topoisomerase-I. 
The samples were loaded on an SDS-PAGE gel and a Western Blot was applied. At the left 
side of each figure are noted the molecular weight marker (MWM) as an overlay of the 
images taken after A) the anti-Topo-I and B) the anti-His-tag antibodies blotting. The 
samples were loaded regarding the incubation time with the IPTG. For each cell line, first 
were loaded the sample without the IPTG, and then samples that collected 1, 2, and 3 
hours after induction. The Arctic Express strain incubated overnight and a sample was 
collected after that too. A) The blotting with the anti-Topo-I antibody. The band of 
interest is placed close to 100kD and also several protein degradation products or 
products derived from incomplete translation are noted at the right part of the figure. 
NS= non-specific products, since protein levels are seen also even before the IPTG 
addition to the culture. B) The blotting with the anti-His-Tag antibody gave a protein 
much smaller than the expected Topo-I size, which was characterised as a NS product.  
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3.5. Attempted expression of Topo-I in 
mammalian cells 
 Since the bacterial expression of Topoisomerase-I potentially gave 
truncated product it was decided to express it in mammalian cells. The plasmid 
which was used was the pZeoTOP1H derived from the pZeoSV2 vector. As 
described in the materials and methods section the plasmid contains the open 
reading frame of C-terminally His-Tagged Topo-I under the control of the SV40 
promoter, which was inserted to the plasmid before the beginning of this project. 
 The plasmid DNA was purified from the bacteria cells and transfected into 
Hela cells by electroporation at conditions described in the materials and 
methods section. In order to be able to calculate the transfection efficiency, an 
accompanied transfection was held using the pmaxGFP vector which encodes a 
green fluorescence protein from the copepod Pontellina plumata. Following the 
epifluorescence microscopy it was seen that there was up to 90% successful 
transfection in the cells, where most of them expressed GFP to some extent 
(Figure 32). Images of the pZeoTOP1H transfection were taken and no 
fluorescence was seen as it was expected (Figure 32). 
 Since the taken results were optimistic for the successful transfection and 
the production of the Topo-I, a purification of the His-Tagged protein was 
attempted by Ni-NTA affinity chromatography as described in section 2.5.4. 
Magnetic beads coated with Ni-NTA agarose purification matrix and are able to 
immobilise and purify proteins carrying a His-Tag. Because this technique has 
high purification affinity, it was considered adequate for the Topo-I purification. 
After the purification a Western Blot was applied, using anti-Topo-I and anti-His 
Tag antibodies, loading all the intermediate and final steps of the purification; 
unfortunately the purification was not successful as the Western Blot did not 
show any sign of protein. Unfortunately time constraints did not allow the 
experiment to be repeated and further data to be collected. 
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Figure 32: HeLa cells transfection with the pZeoTop1H and pmaxGFP vector 
Figures were taken from a Zeiss Axiovert 35 epifluorescence microscope using the Zen 
lite software. Three photos were taken from each sample with approximately 10 cells in 
each field. The images for the pmaxGFP vector green fluorescence were taken using the 
long pass LP520, and the light source for the pZeoTopo-I vector was the HBO100 
mercury lamp (white light). A, B and C show the transfection of the pmaxGFP vector and 
the D,E and F the transfection of the pZeoTop1H vector. In images A) &D) are the cells in 
the bright field of the microscope, B) & E) are the same optical field under the long pass 
LP520 green filter, where the transfected cells fluoresce. In C) & F) images we see the 
overlay of the two images.  
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 The aim of this study was to test the toxicity of heavy metals by 1) 
measuring the level of their ability to inhibit the cell proliferation on MRC5 cells, 
2) the induction level of H2AX phosphorylation and 3) the inhibition level of 
Topoisomerase-I enzyme functions. The latter experiment had metal at more 
physiological concentrations than with previous reported experiments (Stewart 
et al., 1996). 
 The reason of using human lung fibroblasts is the lack of research on 
them, regarding metal toxicity. Yet, the pulmonary system is one of the first 
exposed to metal polluted fumes and dust. Thus, it was of importance to study 
the metal toxic effects on them. Regarding the inhibition of Topo-I function to 
nick and relax DNA, low metal concentrations was tested, since no study before 
has tested the minimum metal concentrations needed to inhibit the Topo-I. Also, 
Stewart et al. (1996) tested only the inhibition of the enzyme's relaxation ability, 
whereas in the present study it is studied the cleavage inhibition as well. 
 The Topoisomerase-I enzyme, were attempted to be purified after 
bacterial and mammalian expression. The bacterial used were E.coli cell strain, as 
the protocol is easy to be followed and new. Although nobody in the existing 
literature appeared to have successfully expressed Topoisomerase-I in E.coli, 
E.coli cell strains promise an increase level of soluble protein yield. In addition, a 
mammalian expression vector containing the open reading frame for hexa-
histidine-Tagged Topoisomerase-I under the control of the SV40 promoter was 
transfected into HeLa cells as another attempt to purify the Topoisomerase-I. 
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4.1. Cadmium 
  The results for cadmium showed that it affects the cell proliferation 
ability and the colony forming capacity drastically, since from the treatment in 
the lowest concentration there was a 50% inhibition of the cell colony formation. 
Higher concentration of the 100μM and 200μM of cadmium were completely 
lethal for the cells, as zero colonies remained after 7 days (section 3.1, Figure 12). 
These results are consistent with similar studies where different cell line was 
incubated with cadmium (Panjehpour and Bayesteh, 2008). Human lung 
carcinoma (Calu-6) cells that were treated with cadmium for 48-72 hours 
showed that 1μM of cadmium was enough to reduce the cells by 20% at 48 hours 
(Panjehpour and Bayesteh, 2008). These authors found that longer incubations 
decreased the cell viability even more, for example in the same concentration of 
1μM incubated for 72 hours decreased the cell viability by 43%. These results 
give evidence to the time and dose relationship of cadmium toxicity. We should 
keep in mind that variation does exist among different types of cells and different 
treatment times make direct comparisons difficult. 
 The formation of γH2AX foci was low in contrast with the radiometric 
drug zeocin. However, foci formation was significantly higher than the negative 
control, at the same used concentrations (Section 3.2.1, Figures 15-16). Several 
previous studies have been reported concerning the ability of cadmium to induce 
γH2AX. For example a study in trout hepatoma cells which, after 24 hours of 
cadmium treatment at 50μM, showed phosphorylation of H2AX (Krumschnabel 
et al., 2010). However, no studies have been conducted regarding lung fibroblasts 
cells. 
 The inhibition of Topoisomerase-I ability to cleave and relax DNA was 
tested at linear and supercoiled circular DNA, respectively. Both experiments 
gave similar results that cadmium is able to inhibit the Topoisomerase-I even in 
very low concentrations of 3μM (Section 3.3.2, Figures 21-22) and (Section3.3.3, 
Figure 29A). As mentioned above only one study has been published on cadmium 
and Topoisomerase-I and this gave positive results for inhibition of the enzyme's 
relaxation ability, however in the high non-physiological concentration of 5mM, 
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 The results from the clonogenic assay in MRC5 cells showed an L.D.50 of 
66μM. In contrast to cadmium, the cell proliferation decreased gradually under 
lead treatment. In the lowest used concentration (12.5μM) the cell survival was 
at the 80% and no less than 70% in the treatment with 25μM of lead (section 3.1, 
Figure 12). During a cell survival investigation on rat vertal mesencephalic 
neurons, a significant decrease of TH+ cells length was observed at very low lead 
concentrations (until 0.1μM) after 48 hours of treatment, which can stimulate 
overt cell death (Schneider et al., 2003). Even though I did not use such low 
concentrations of lead and I have not compared the effects on cell size, it is still 
possible to see that the cell survival was affected even at the lowest 
concentration after 24 hours of treatment with lead. 
 For γH2AX induction, lead produced the highest response in comparison 
to the rest of the metals (section 3.2.1, Figures 15-16). Several studies have 
tested lead toxicity by measuring the induction of γH2AX. For example, it has 
been demonstrated that lead can bind to histones leaving the DNA unprotected 
(Quintanilla-Vega et al., 2000). The induction of γH2AX foci as a marker of DNA 
damage has been conducted in increasing duration of lead exposure, reaching a 
maximum number of foci at 24 hours (Gastaldo et al., 2007). A more recent study 
showed that lead could initiate the phosphorylation of γH2AX in the human B3 
cell line after treatment with 100mM lead for 24 hours. Specifically the foci 
appeared close to or at the telomere, which indicates a possibility of short or 
dysfunctional telomeres, rather than the formation of a DSB (Pottier et al., 2013). 
The results of this thesis give additional data to support the induction of γH2AX 
at lung cells, as gave the most increased levels of γH2AX comparing with the 
other of the tested metals. 
 A possible paradox was apparent when the effects of lead Topoisomerase-
I inhibition was studied. Lead was shown to inhibited enzyme function in the 
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relaxation assay (Section 3.3.3, Figure 29B) but not in the cleavage assay (Section 
3.3.2, Figure20). This observation could be explained by the possibility that lead 
inhibits Topoisomerase-I by a different mechanism by binding to the enzyme at a 
different site, not similar to the other metals tested here. In the relaxation assay 
the inhibition was apparent as low as the 12.5μM of lead per reaction. It is 
possible that lead does not inhibit the strand cleavage step of Topo-I, and instead 
inhibits its function at some other step No study before have been tested before 
the lead effects on the Topo-I function, thus the present result shows the possible 




 There are comparatively few studies of copper toxicity in healthy cells.  In 
the present study copper showed a decrease in the colonies' number reaching 
the 20% of survived colonies at 200μM and the L.D.50 being around 55μM 
(section 3.1, Figure 13). A variety of studies have been conducted though, testing 
the apoptotic activity and the metallathionein mechanism for cadmium toxicity 
suggesting copper complexes as an antitumor agent.  An intermediate inhibition 
of several tumours, among them and in lung carcinomas, and induction of 
apoptosis was observed after incubation with nanomolar copper concentrations 
(Easmon et al., 2001). However further experiments are needed before reaching 
a conclusion regarding the role of copper in inhibition of cancer cells. A study on 
hepatocytes suggested that when cells sequester large amounts of copper (16μM 
and above), toxic effects appeared including delayed cell-cycle progression, a 
gradual loss of replicative capacity, and an increased incidence of cell death 
(Aston et al., 2000). This study comes in accordance with the present project 
where the toxic effects appeared showed that even a short exposure is enough to 
decrease cell viability. 
 For the induction of γH2AX, copper had the second highest response after 
lead. Other studies on γH2AX are limited in copper (section 3.2.1, Figures 15-16). 
The reason for that is the known redox activity of copper and its limited toxic 
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effects (Nakajima et al., 2013). The research on copper is limited so a direct 
comparison cannot be made, however several are the studies on copper 
complexes, like for example a recent study on HeLa cells exposed to 60μM Cu(II)–
mal–picoline complex (Biswarup et al., 2012). 
 Interesting results were found for Topoisomerase inhibition by copper. As 
mentioned above human topoisomerase I inhibition has given positive results in 
the high copper concentration of 5mM (Stewart et al., 1996). Comparing to this 
study much lower copper concentrations showed to inhibit Topo-I cleavage 
activity which were reaching down to 25μM. However, in concentrations 
between 6 and 3μM approximately, stimulation of the enzyme was seen, as 
bigger quantity of the cleavage product was produced (section 3.3.2, Figure 23). 
On the other hand, in the relaxation assay little inhibition of the enzyme was 
found. Further studies are required to find the possible role of copper at cleavage 
function of topo-I. Topo-I is similarly important for cell survival and further 
studies are required to find the mechanism and the binding site and also the 
reversibility of the effects (Section 3.3.3, Figure 29C). 
 
4.4. Zinc 
 Clonogenic survival assay showed very similar results between copper 
and zinc, giving a L.C.50 of around 55μM (section 3.1, Figure 14). Zinc is normally 
present at concentrations lower than the lowest concentration tested, so the 
toxic effects observed are not inconsistent with zinc's essential function. This is 
logical considering that the zinc is a trace element in the human body and its 
essentiality is limited at 2-3gr/70 kg of a healthy adult. Due to zinc's role in the 
function of many enzymes and proteins, there have been limited studies testing 
zinc's toxicity itself. In a previous study testing various glioma and bone marrow 
cells have been treated at increasing concentrations of zinc. The results showed 
the time variability of the results depending on the cell type and the dose 
relationship. Only the U87MG cell line growth was affected significantly after 120 
hours of 100μM zinc treatment (Roosen et al., 1994). This study presents the 
toxic effects of exposure to zinc at MRC5 lung fibroblasts. 
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 In the immunofluorescence assay detecting the phosphorylation of H2AX 
the results of the zinc and copper are once more similar, with very little 
decreased results produced after zinc treatment. However, the results are not 
directly comparable between the two metals because of the different 
concentrations tested. The MRC5 cells were treated with 125μM of zinc and 
200μM of copper. It is possible that the results could have been even more 
similar if the cells were treated with the same concentrations of the two metals 
(Section 3.2.1, Figures 15-16). 
 For the inhibition of Topo-I the results taken from the cleavage and 
relaxation assays came in total agreement. Zinc is able to inhibit Topo-I in the 
same concentrations during both assays. The highest tested concentrations of 
zinc were shown to inhibit close to 100% the cleavage assay (Section 3.3.2, 
Figure 25) and a very clear inhibition were also observed at these concentrations 
in the relaxation assay (Section 3.3.3, Figure 29D). The stimulation of the enzyme 
should be considered and be tested further at future research, because a 
complicated mechanism could be hidden between the Topo-I and the zinc in very 
low concentrations. However, the large standard deviation should not be 
forgotten as well. Zinc inhibition of Topo-I relaxation ability has also been tested 
by (Stewart et al., 1996) in the high concentration of 5mΜ, so it is difficult to 
compare the results and explain the stimulation effect that was observed in my 
results (Section 3.3.3.).  
  
4.5. Topoisomerase-I expression 
 The first studies that were conducted on Topoisomerases, were isolating 
eukaryotic Topoisomerases from rodents in order to identify the role of the 
enzyme during the cell cycle or in the interference of others proteins induction 
(Cobb J et al., 1997; Yves Pommier et al., 1990). Previous experiments expressed 
the Topo-I successfully in yeasts strains (Mary-Ann Bjornsti et al., 1989) and in 
Baculovirus (Stewart et al., 1996)  but the full active enzyme after expression in 
E.coli has not been reported. The purification of the protein will give a more 
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easily manipulated protein which could be used for future experiments, to 
further study the mechanism of its metal-dependent inhibition.  
 Wild type human Topoisomerase-I has been attempted to be expressed in 
bacterial strains (section 3.4) and in mammalian cells (section 3.5). 
Unfortunately, both attempts have not given a full protein, however both of them 
have prospects for positive results. At this project it was seen that several 
products derived from incomplete translation or from protein degradation. Even 
though an active protein was not purified the fact that the degradation products 
were taken for the first time gives positive results for future approaches of the 
expression and purification of the protein.  
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 With the completion of this project more evidence were given about the 
metals' toxicity used in low levels, giving strong support of the cancerogenic 
ability of those metals. Standing as preliminary data, this study encourages 
further research towards understanding the mechanism of the metals' binding to 
the Topo-I enzyme and if that binding is reversible. The expression of the protein 
is the next step that should be taken so that the manipulation of the proteins' 
active sites will give great understanding of the Topo-I action. 
 The cancerogenicity of cadmium and lead and the toxic effects of zinc and 
copper are very well acknowledged, however the inhibitory effects on the Topo-I 
add one more protein affected by those metals. Topo-I is a protein which has not 
been thoroughly studied and has stayed in the dark compared with the rest 
family-proteins. This study has potential novel future results focusing on the 
vicinal cysteines 504 and 505 which have been suspected to be the target of the 
metals, due to their thiol groups and could possibly be of use in a drug therapy 
field. Several metal complexes have been used over the years in cancer 
treatment. Thus, metal complexes focusing on cancer cells combined with their 
ability to bind specifically to Topo-I should be seriously considered and further 
be studied for future cancer drug development. 
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APPENDIX A- Topoisomerase-I cleavage inhibition by 
heavy metals 
Figure 33: Topoisomerase-I cleavage function inhibition by heavy metals, data 
from all experiments. 
See Section 3.3.2. for experimental detail. 
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APPENDIX B- Topoisomerase-I cleavage inhibition by 
cadmium 
Figure 34: Topoisomerase-I cleavage function inhibition by cadmium, data from 
all experiments. 
See Section 3.3.2.1. for experimental detail. 
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APPENDIX C- Topoisomerase-I cleavage inhibition by 
copper 
Figure 35: Topoisomerase-I cleavage function inhibition by copper, data from all 
experiments. 
See Section 3.3.2.2. for experimental detail. 
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APPENDIX D- Topoisomerase-I cleavage inhibition by 
zinc 
Figure 36: Topoisomerase-I cleavage function inhibition by zinc, data from all 
experiments. 
See Section 3.3.2.3. for experimental detail. 
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APPENDIX E-vector maps 
 The pET28a-c vectors carry an N-terminal His Tag /thrombin/ T7 Tag  
configuration plus an optional C-terminal His Tag sequence. Unique sites are 
shown on the circle map. Note that the sequence is numbered by the pBR322 
convention, so the T7 expression region is reversed on the circular map. The 
cloning/ expression region of the coding strand transcribed by T7 RNA 
polymerase is shown below. The f1 origin is oriented so that infection with 
helper phage will produce virions containing single-stranded DNA that 
corresponds to the coding strand. Therefore, singlestranded sequencing should 
be performed using the T7 terminator primer (Novagen). 
 The maps for pET-28b(+) and pET-28c(+) are the same as pET-28a(+) 
(shown) with the following exceptions: pET-28b(+) is a 5368bp plasmid; 
subtract 1bp from each site beyond BamH I at 198. pET-28c(+) is a 5367bp 
plasmid; subtract 2bp from each site beyond BamH I at 198. 
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 The pZeoSV vectors are 3.5-kb vectors designed for high-level, 
constitutive expression in mammalian cell lines that express the SV40 large T 
antigen. The Zeocin™ resistance gene provides fast and efficient selection in E coli 
and mammalian cells that do not express the SV40 large T antigen. The vectors 
have the following features which make them efficient: SV40 enhancer-promoter 
and origin for high-level, constitutive expression and replication in mammalian 
cells; BGH polyA signal for efficient processing of mRNA transcripts; Multiple 
cloning site in the forward (+) and reverse (-) orientations for easier cloning; 
Small size for efficient cloning; f1 origin for the rescue of single-strand DNA 
(sense strand); pUC origin of replication for growth in E.coli. Expression of the 
Zeocin™ resistance gene is driven by the CMV promoter in mammalian cell lines 
and by the synthetic EM-7 promoter in E.coli. pZeoSV2 can be used in transient 
expression assays as well as to create stable cell lines. 
 
